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ABSTRACT 
 
A PEPTIDE-BASED PLATFORM FOR DISPLAYING ANTIBODIES 
TO ENGAGE T CELLS 
 
 
 
By 
Ying Zheng 
December 2010 
 
Dissertation supervised by Wilson S. Meng, Ph.D. 
    This study investigated a strategy by which antibodies were displayed on a gel-like 
substance to engage T cells.  The substance, a peptidic composite, was characterized in 
vitro and explored as an injectable system in vivo. The composite consists of two 
amphiphilic peptides, AEAEAKAKAEAEAKAK (referred to as “EAK”) and 
AEAEAKAKAEAEAKAKHHHHHH (“EAKH6”). Spectroscopic analysis showed the 
two peptides integrated into a single structure. Prior to combination, conformational 
analysis revealed that EAKH6 adopts a mixed -helix/-strand conformation. In the 
presence of EAK, EAKH6 exists predominantly in a -strand conformation. Using 
nickel-bound horseradish peroxidase as a probe, the composite of EAK-EAKH6 was 
found to display His-tags. T-cell-specific antibodies were found stably displayed on the 
  
v 
EAK-EAKH6 assembly using recombinant protein A/G and anti-hexahistidine antibody 
as an adaptor. When mounted with an anti-CD4 antibody, the system was shown to 
capture CD4 T cells in a mixed population of lymphocytes. Antibodies were concentrated 
in the subcutaneous space in mice when co-administered with EAK and EAKH6 along 
with protein A/G and anti-hexahistidine antibody as an aqueous (deionized water) 
solution. Taken together, these results indicate that the design can be used as a platform 
for engaging specific subsets of leukocytes for purpose of immune modulation.   
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CHAPTER 1      
INTRODUCTION 
 
    Monoclonal antibodies (mAb) represent an important class of therapeutics. In the 
United States alone, more than 20 antibody and similar molecules are currently approved 
for a variety of diseases, including cancer, autoimmune and inflammatory diseases. 
[1, 2]
 
Of the 26 new drugs approved in 2009 by the U.S. Food and Drug Administration, four 
are mAb. Currently, more than 200 Abs are presently in various stages of clinical 
development.
[1] 
Among these are several that aim to modulate functions of T cells 
through blocking or activating cell surface molecules, including CD3, CD4, CD25, and 
cytotoxic T lymphocyte antigen-4 (CTLA4).
[2, 3]
 These modes of action preserve the 
overall T cell populations but alter a subset of cells in order to modify the course of the 
disease.     
    Normally, T cells accumulate and recirculate within secondary lymphoid organs 
(spleen and lymph nodes). In pathological conditions, these lymphocytes flux robustly to 
diseased locales to release cytokines and factors that, in most instances, sustain or 
accelerate the condition. For example, T cells reactive against antigens expressed by 
islets of Langerhans infiltrate into pancreas of patients with insulin-dependent diabetes 
mellitus. 
[4]
 In malignant cancers, regulatory T (Treg) cells populate tumors and promote 
tumorigenesis by suppressing the functions of other immune cells.
[5]
 The rationale for 
using antibodies is that the high specificity and binding strength of antibodies allow them 
to bind to the target cells or block the signal pathway, leading to the depletion or 
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deactivation of the bound T cells. In pre-clinical and clinical settings of cancer or 
autoimmunity, T cell-specific antibodies are typically administered systemically. 
[3, 6, 7]
 
Consequently, all T cells (and sometimes other leukocytes that express the target epitope) 
are affected, leading to non-specific immune modulation, which can result in adverse 
events in patients.
[8]
 Thus, the intrinsic specificity of an anti-T cell mAb is lost when 
delivered systemically. Proposed here is a strategy by which disease-driving T cells 
operating locally can be selectively engaged (and altered phenotypically) as a means to 
induce specific immune modulation.        
     The peptide AEAEAKAKAEAEAKAK (single amino acid code; hereafter “EAK”) 
self-assembles into high-molecular-weight structures.
[9] 
The EAK sequence encompasses 
periodic repeats of alternating polar and nonpolar residues. In pure water, the peptide 
adopts a β-strand conformation in which the polar and non-polar side chains orient 
toward opposite sides. In the presence of monovalent metal ions, the β-strands self-
associate into nano-scaled fibers through inter-sheet ionic pairing between charged 
residues (glutamate and lysine) and hydrophobic interaction between alanines.
[9-11] 
Subsequent spontaneous cross-linking of the fibers yields quaternary β-sheet structures 
resistant to acids and proteases.
[11]
 These networks of interwoven peptidic fibers have 
been explored as scaffolds for tissue growth or regeneration through cell attachments.
[12] 
Such matrices have the potential to provide molecular cues for a variety of cells to grow 
and differentiate. An area of application that has not been explored is to use the fibrillar 
structures to enhance the therapeutic functions of Abs. The objective is to use mAb to 
intercept migratory leukocytes participating in cancer pathogenesis. The central 
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hypothesis of this research is that an injectable EAK-based system can be developed to 
engage specific T cells via monoclonal antibodies.      
     To transform EAK matrices into a structure that will engage specific cells, a versatile 
recognition mechanism is needed. To this end, a modified EAK peptide with six 
consecutive histidines (H6) appended at the C-terminus was used to introduce binding 
sites. The H6 domain is recognized by anti-polyhistidine antibodies and metal ions such 
as nickel through coordination bonds, making this a multifunctional platform. The 
modified peptide, referred hereafter as “EAKH6”, was designed on the basis that the 
amphiphilic domain (AEAEAKAK)2 would intercalate into the crossed β-sheets of EAK 
to form a composite in which H6 domains extend from the peptide assembly. We 
envisaged that the histidine appendage would not hinder the ability of the amphiphilic 
domain in EAKH6 to engage the same as in EAK. In the meantime, it is hypothesized 
that the incorporation of EAKH6 does not interfere with the self-association of EAK. 
    This work was motivated by the need for new strategies to localize anti-T cell Ab to 
the site of action. Described herein are characteristics of a peptide-based system 
developed as an Ab displaying platform, made possible by the use of a bi-functional 
peptide containing a β-strand domain and a H6 domain.  Integration of EAKH6 into EAK 
β-sheets was confirmed in that a composite of the two contained imidazole, the side chain 
of histidine. EAKH6 appeared to transit from a mixed α-helix/β-strand conformation to a 
predominately β-strand conformation in the presence of EAK. Display of functional H6 
domains in the EAK-EAKH6 composite was evidenced in the experiments showing that 
HRP-Ni and IgG were captured through coordination bonds or via the adaptor protein 
A/G complexed with anti-H6 Ab, respectively.  EAK-EAKH6 but not EAK capture cells 
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when mounted with anti-CD4 IgG; a subset of CD4+ T cells expressing CD25 and Foxp3 
was depleted form cell suspensions containing different lymphocytes. Thus, the EAK 
structure was transformed from a non-specific matrix to a cell-selective structure in EAK-
EAKH6 construct. The system proved to be amenable as an injectable material.  In vivo, a 
solution of EAK, EAKH6, protein A/G, anti-H6 Ab and IgG-PE injected subcutaneously 
associated to concentrate the fluorescent Ab at the injection site for at least 24 h. The 
EAK-EAKH6 composite thus serves to cluster antibody molecules. Such clustering 
reduces the entropic loss upon antigen binding, thereby increasing the collective avidity 
of the Ab. This should in theory result in superior efficacy of EAK-EAKH6 associated 
Ab compared to free Ab.      
    This dissertation consists of  nine chapters. Chapter 1 provides an overview of the 
work that includes a brief introduction to mAb, the design of EAK-EAKH6 composite, 
and the main experimental results and conclusions. Within the chapter an elaboration of 
the central hypothesis and the scope of the work can be found. In Chapter 2 the 
significance of the research is discussed. The advantage of using EAK-EAKH6 assembly 
to cluster antibodies with increased avidity is addressed. Chapter 3 provides a review of 
literatures concerning the background information as well as relevant recent studies and 
discoveries. The first part concerns T cell differentiation and activation in health and 
diseases. In particular, the change of Treg cells in cancer patients. Secondly, the 
mechanisms and factors governing assembly of amphiphilic peptides are addressed. 
Applications of peptide scaffolds in drug delivery and 3-D cell cultures are also reviewed. 
Chapter 4 presents analytical data supporting the formation of EAK-EAKH6 composite. 
Spectroscopic data confirming the presence of EAKH6 in the composite are provided. 
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The mechanism of EAKH6 integration into EAK is also addressed. The function and 
stability of H6 domains were evaluated. Chapter 5 reports the feasibility of using protein 
A/G as an adapter to load the EAK-EAKH6 composite with antibodies. Evidence of 
formation of the antibody-mounted peptide assembly in vivo is also presented. Chapter 6 
details the investigation of the capability of anti-CD4 EAK-EAKH6 assembly to capture 
Treg cells. Chapter 7 describes the development and characterization of submicron 
PLGA particles used to deliver nucleic acids, particularly, the encapsulated 
oligodeoxynucleotide (ODN) and the surface adsorbed siRNA. The improved in vitro 
uptake efficiency to primary mouse leukocytes is reported. The investigation of in vivo 
function of siRNA carried by PLGA particles in mouse melanoma model is also 
described. These particles may be loaded onto the EAK-EAKH6 as a drug delivery 
module. Chapter 8 is a narration of the overall conclusions of the studies and 
contributions of this research to the biomaterial community. The last chapter is included 
as chapter 9, for it contains data generated outside the scope of the work towards testing 
of the main hypothesis.  
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CHAPTER 2      
SIGNIFICANCE OF THE RESEARCH 
 
    First introduced by Köhler and Milstein in 1975, mAb represent a mainstay in 
biological therapeutics and biotechnology.
[1, 13]
 The mechanisms by which mAb modulate 
the functions of their target antigens are diverse. These include binding and neutralizing 
soluble cytokines and growth factors to prevent them from activating their cognate 
receptors. An example for this is the first therapeutic antibody, infliximab (Remicade; 
Centocor/Merck), which binds tumor necrosis factor (TNF). Binding of ligands to 
receptors can also be blocked by mAb directed to their cognate receptors and inhibit 
receptor activation or function, for example, tocilizumab (Actemra/RoActemra; 
Chugai/Roche) targeting the IL-6 receptor. Another class of mAb binds to cell surface 
antigens and depletes antigen-bearing cells through complement-mediated lysis and 
opsonization, as well as Fc receptor for IgG mediated clearance. Rituximab 
(Rituxan/Mabthera; Genetech/Roche/Biogen Idec), which is a chimeric CD20-specific 
antibody, succeeded in achieving B cell depletion in lymphoma patients. Therapeutic 
mAb can also induce active signals that alter cellular fates. Binding of the T cell receptor 
(TCR)-CD3 complex by teplizumab (MGA031; MacroGenics/Eli Lilly) can induce an 
altered pattern of cytokine production favoring IL-10 rather than interferon-γ (IFN-γ) 
expression. Hence, this mAb modulate T cell function by altering T cells from an 
activating phenotype to potentially a tolerizing phenotype.
[1, 2, 14]
 Besides CD20 and CD3, 
there are hundreds of surface molecules identified for leukocytes, numbered to 350 for 
humans most recently.
[15]
 These molecules are not merely markers on the cell surface to 
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define leukocytes; they also play an important role in cell activities, such as acting as 
receptors. Therefore, these molecules are critical because both innate immunity and 
adaptive immune responses depend upon the activity of leukocytes. Currently, half of the 
24 therapeutic antibodies on the market target surface molecules of leukocytes. 
[1, 2]
 It 
remains to be a huge pool of new targets to generate mAb as effective treatments for 
diseases. 
    The prowess of mAb lies in their specificity and high affinity towards cognate target 
molecules. When given intravenously (i.v.), however, these two features are inevitably 
diluted. Specificity is diminished when all leukocytes are affected when the drug is 
intended in only a subset T cells participating in the disease. Affinity is overshadowed 
when only a small concentration of the i.v.-infused mAb reached the target cells. New 
strategies overcoming these limitations would make possible the full realization of mAb‟s 
therapeutic potential.  
    A simple way to enhance the binding strength of antibodies is the strategy of 
multivalency. An antibody‟s affinity is defined as the strength of the binding to its 
cognate antigen.  Affinity is typically quantified by the dissociation constant, Kd, of an 
individual epitope (of the antigen) from an individual antibody-binding site. 
[4, 16, 17]
   
                                    

AgAbAgAb 
                                       

Kd 
[Ag][Ab]
[AgAb]
                                       Equation. 2-1 
    This specific energetic relationship between one antibody binding-site and its 
complementary antigenic determinant is described by the “intrinsic” affinity. This is the 
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affinity that is displayed by a monovalent fragment, and it also describes any binding of 
either monovalent or multivalent immunoglobulin to soluble, identical, monomeric 
antigens.
[16-18]
 In case of polymeric antigens or surface antigens, such as receptors 
distributed on a cell surface, the measured affinity can be considerably enhanced by the 
formation of multiple binding interactions. The term “avidity”, or “functional affinity” 
was then introduced to describe the enhancement of binding strength by multivalency.
[16-
18]
 Although avidity is the accumulated strength of multiple affinities summed up from 
multiple binding interactions, it is usually more than the sum of the individual affinities 
quantitatively. Single-chain antibody fragments (scFv) are comprised of individual 
antigen-recognition sites from a mAb and have proven to be a very useful tool for 
investigating the role of affinity and avidity. Through phage display, an anti-human Her2 
(also designated as CD340, overexpressed on the surface of breast cancer cells) scFv, 
G98A, was generated and the binding affinity was determined as Kd=3.2×10
-7 
M. G98A 
was also successfully expressed as IgG variants, which containing two antigen binding 
sites. The Kd (now is avidity for the IgG molecules) was found increased to 5.0×10
-10 
M.
[19]
 It thus appears that avidity can be modulated exponentially by changing the 
valence of the mAb in a given system. A number of quantitative approaches for 
multivalency have been developed. Diabodies, triabodies, and even tetrabodies were 
designed from examples of scFv molecules and applied in virus and cancer targeting.
[19-
21]
 However, the gain contributed by the second binding site is only observed if the 
antigen is on a surface or is polymeric.
[18]
 Hence multivalent design is not an applicable 
strategy for mAb targeting to soluble cytokines. While the multi-expression of surface 
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molecules on T cells make it possible to improve the functional affinity of corresponding 
mAb through multivalency. 
        Based on the theory described above, the conceptual innovation of this research is to 
exploit antibody clustering to capture T cells. A composite material consisting of two 
peptides, EAK and EAKH6, was developed for this purpose. EAK is an amphiphilic 
peptide, which self-assembles to form a β-strand-based macroscopic structure upon 
injection.
[10]
 EAKH6 is designed to provide H6 domains extending out as mounting sites 
when the rest of the peptide is intercalated into the β-strands. With this design, mAb can 
be immobilized onto the EAK-EAKH6 composite using an adaptor (protein A/G 
complexed withanti-H6 antibody). In contrast to soluble antibodies operating 
independently from one another, this composite serves to congregate a collection of 
antibody molecules displayed in the same orientation. Once the first antigen has reached 
the binding site, the whole cell experiences a reduction in mobility, the other antigens 
being restricted to the neighborhood for a second antibody to establish an additional 
connection.
[18, 22]
 In these multiple interactions, rebinding can occur when one antigen 
dissociates.
[20] 
After complete adsorption has occurred, several surface antigens have to 
leave simultaneously before the whole cell is desorbed, thereby make the process 
irreversible.
[23]
 The increased in avidity makes it extremely difficult for the target cell to 
dissociate (figure 2-1), unless the composite disintegrate. Cells interacting with the 
antibodies cannot digest the structure when the size of the peptide assembly (mm) 
exceeds the limit of endocytosis.
[24]
 The theoretical justification for this is that when 
soluble antibodies bind to cell surface antigens, the decrease in disorderness (-ΔS) in the 
system must compensate by enthalpic changes (ΔH), namely electrostatic interactions at 
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the antigen-antibody interface (figure 2-1 a). However, if multiple antibody molecules 
were immobilized on a surface in a defined area, there should be small or no net change 
in entropy upon binding to antigens. In this scenario the enthalpic change would 
dominate Ab-Ag association. Thus the design is underpinned by thermodynamic 
considerations.  
    Additionally, the injectable and self-assembling properties of EAK render the system 
described above a local delivery strategy at the pathological sites for mAb. Intravenous 
injection is often incapable of delivering functional mAb or their fragments to the target 
tissue, as many mAb are degraded in the blood, are captured by receptors and non-
specific binding sites. Furthermore, systemic administration of mAb is always 
accompanied with severe adverse effects, especially for those leukocytes-targeted mAb. 
Examples include teplizumab (anti-CD3 mAb), which inhibits acute allograft rejection by 
T-cell depletion, increases the risk of infection and cancer.
[25]
 Inhibition of CTLA-4 in 
patients using ipilimumab represents a new and promising strategy to induce tumor 
regression. However, immune-related adverse events (IRAEs) such as rash, colitis and 
hepatitis are also observed.
[26]
 Collectively, local rather than systemic delivery may be the 
preferred route of mAb delivery to modulate the immunity of host. 
    Our long-term goal is to modulate immunity locally at the pathological sites. The 
studies presented justify the utility of self-assembling peptides as a platform to display a 
collection of mAb. The concept of enhanced binding strength through multivalency 
(avidity) is applicable by placing multiple antigen-binding moieties in a close physical 
proximity (“clustering”). The described experiments suggest the possibility to engage 
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specific subset T cells via immobilized surface molecule-targeted mAb. This prospect 
might lead to new treatments using mAb with higher specificity and binding strength.  
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Figure 2-1: Schematic of affinity and avidity of antigen-antibody binding. (a) 
individual antibodies, (b) a collection of antibodies immobilized on a surface.  
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    CHAPTER 3      
LITERATURE REIVEW 
 
T CELLS IN HEALTH AND DISEASES 
  Cells in immune system 
    The immune system in vertebrates encompasses components and processes that 
collectively mitigate and limit harmful effects of pathogens through elimination or 
neutralization. Macrophages and neutrophils of the innate immune system provide a first 
line of defense against many common microorganisms and are essential for the control of 
common infections. However, this defense depends on invariant receptors recognizing 
common features of pathogens, which can be overcome by mutational structural changes. 
Lymphocytes in the adaptive immune system have provided a more versatile means of 
defense with the capability of memory by which subsequent infection by the same 
pathogens can be arrested early on. 
    Adaptive immune responses depend upon lymphocytes, of which there are two major 
types: B cells and T cells. Both B and T lymphocytes originate in the bone marrow, but 
only the B lymphocytes mature there; the precursor T lymphocytes migrate to the thymus 
to undergo their maturation. The sole effector function of B cells is to produce 
immunoglobulin as defense against pathogens in the extracellular fluids. This antibody-
mediated response, also known as humoral immunity, is not effective against intracellular 
pathogens such as parasites and viruses, or genetically transformed cells like tumors. 
Coordination of T and B cells responses are required to mount effective immunity.  
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T cell activation and differentiation 
    Once matured in the thymus, T cells leave and remain recirculating between blood and 
peripheral lymphoid tissue. Naive T cells, those that have not yet encountered their 
cognate antigens, remain resting until being stimulated by antigen-presenting cells 
(APCs).  APCs engage naive T cells‟ antigen recognition receptor (or T-cell receptor; 
TCR) through major histocompatibility complex (MHC) molecules in which antigen 
fragments (peptides) are presented. This specific interaction requires augmentation by a 
second signal, or co-stimulation, figure 3-1. Effector T cells fall into two major functional 
classes distinguished by the expression of the cell-surface proteins CD4 and CD8. 
Peptides from intracellular pathogens that multiply in the cytoplasm are carried to the cell 
surface by MHC class I molecules and presented to CD8 T cells. They then differentiate 
into cytotoxic T cells that kill infected target cells. Peptide antigens from pathogens 
multiplying in intracellular vesicles and those derived from ingested extracellular bacteria 
and toxins, are carried to the cell surface by MHC class II molecules and presented to 
CD4 T cells. They then differentiate into helper T cells that activate other cells such as B 
cells and macrophages. 
    Only dendrtic cells (DCs), macrophages, and B cells are able to express MHC 
molecules as well as the co-stimulatory cell-surface molecules (B7 molecules). The 
receptor for B7 molecules on the T cell is CD28. Ligation of CD28 by B7 molecules is 
absolutely required for the clonal expansion of naive T cells and their differentiation into 
armed effector T cells. The most potent activators of naive T cells are DCs, and they are 
thought to maintain T cell homeostasis in vivo. Precursor or immature DCs take up 
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Figure 3-1: Activation of naive T cells requires two independent signals. (a) 
The binding of the peptide: MHC-II complex of APCs to the TCR:CD4 complex of 
T cells results in a signal (signal 1) to the T cell that antigen has been recognized. 
Activation of naive T cells requires a second “co-stimulatory” signal (signal 2) that 
is provided by (b) the binding of the T cell CD28 receptor to the APC B7 molecule. 
(c) An APC will neither activate nor inactivate a T cell if the appropriate antigen is 
nor present on the APC surface, even if it expresses a co-stimulatory molecule 
and can deliver signal 2. However, when a T cell recognizes antigen in the 
absence of co-stimulatory molecules, it receives signal 1 alone and is 
inactivated.[4] Reprinted with permission from ©2005 Garlan Science Publishing: 
[Immunobiology] (6th edition, page 328,339). 
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antigens by phagocytosis and macropinocytosis at inflammatory locales and subsequently 
migrate to draining lymph nodes. Therein DCs engage T cells flux from tissues 
continually. Dual fulfilment of MHC-TCR and co-stimulation leads to activation of T 
cells. This stringent requirement serves to minimize T cells from responding to self-
antigens expressed in normal tissues, which lack co-stimulatory activities. Antigen 
recognition in the absence of co-stimulation inactivates naïve T cells, inducing a state 
known as anergy, in which proliferation and differentiation are prevented, figure 3-1 c. 
Subsets of helper T cells 
    CD4+ helper T cells regulate immune responses via the production of soluble factors 
that instruct other cellular elements of the immune system. The first well-defined helper 
T cell subsets are TH1 and TH2 by Mosmann and Coffman in 1986.
[27]
 TH1 effector cells 
are characterized by production of IFN-γ, and are thought to be responsible for activating 
macrophages and enabling them to kill intracellular and ingested pathogens. TH1 cells 
also produce IL-2, which is required for the proliferation of CD8 T cells. TH2 cells are 
defined by production of IL-4 as well as the related cytokine, IL-13. TH2 cells are 
considered the classical helper T cells providing help to B cells to generate class-
switched antibodies. Indeed, when TH2 cells are preferentially induced, the main response 
is humoral immunity. Generally speaking, exposure to IL-4, IL-5, IL-9, IL-10, and IL-13 
favors the development of TH2, whereas IL-12 and IFN-γ favor TH1 cell development.
[28-
30]
 In 2005, the IL-17 producing cells, named TH17, were classified as a new subset of 
CD4+ helper T cells.
[31, 32]
 Activation of precursor T helper cells in the presence of TGF-
β and IL-6 is thought to drive differentiation of TH17 cells. TH17 cells are thought to be 
particularly important in maintaining barrier immunity at mucosal surfaces, such as the 
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gut and lungs, as well as the skin. Consistent with this, TH17 cells are highly prevalent in 
the mucosal tissues of healthy individuals. The fourth main subset of CD4+ T cells is 
regulatory T cells (Treg cells), characterized by expression of the transcription factor 
Foxp3. Treg cells can emerge directly from the thymus or induced in the periphery from 
naive CD4+ T cells through TGF-β.[29, 33] 
   Many diseases can be characterized as an abnormal change in the polarization of T cells. 
For example, in AIDS patients, HIV infection initiates a rapid and substantial decline in 
CD4+ T cells. 
[34]
 In inflammatory allergic reactions, for example, asthma, are associated 
with the production of IgE antibodies against common, innocuous antigens. IgE antibody 
production requires TH2 cells that produce IL-4 and IL-13, and it can be inhibited by TH1 
cells. The presentation of low does of antigen can favor the activation of TH2 cells over 
TH1 cells, and many common allergens are delivered to the respiratory mucosa by the 
inhalation of a low dose. On the other hand, delayed-type hypersensitivity reactions, e.g., 
insect venom caused local skin swelling and erythema, are mediated by TH1 cells and 
CD8 cytotoxic T cells.
[4, 35]
 Beyond the TH1 and TH2 subsets, TH17 cell have recently 
been identified as important in the response to pulmonary and colonic bacterial 
infections.
[36, 37]
 Commensal gut floras contribute to the expansion of TH17 cells, leading 
to inflammatory bowl diseases (IBD). IL-17 mRNA has been also found to be highly 
expressed in inflamed mucosa from IBD patients. More recently, it has been shown that 
TH17 cells present in tumors.
[38]
 While the cause-effect relationship between TH17 cells 
operating in tumors has been controversial. Evidence is accumulating to suggest that 
TH17 cells can promote protective antitumor immune response.  
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Regulatory T cells 
   Deficiency of Treg cells (in frequency or functions) can result in severe autoimmune 
syndromes, such as massive lymphatic proliferation, diabetes and enteropathy.
[39]
 
Conversely, an increased level of Tregs often occurs in malignancies, allowing the 
tumors to circumvent host immune attacks.
[40, 41]
 First described in the 1970s as 
“suppressive T cells”, this elusive subset is now named “regulatory T cells” with much 
renewed interest.
[39, 40, 42, 43]
 In 1995, Sakaguchi and coworkers showed that the 
interleukin-2 (IL-2) receptor α-chain, CD25, is constitutively overexpressed on CD4+ 
regulatory T cells. These CD4+CD25+ cells constitute approximately 10% of the total 
peripheral CD4+ T cells. It is now generally accepted that this subset contributes to the 
maintenance of self-tolerance by down-regulating immune responses to both self and 
non-self antigens in an antigen specific and non-specific manner. 
[44]
 
    Treg cells have been extensively studied in a variety of physiological and pathological 
conditions in mouse and man. The data support the fact that Treg cells suppress 
responder (CD8+) T cells and myeloid cells by secreting suppressive cytokines (e.g., IL-
10, TGF-β), competitively consuming IL-2, and inducing cytolysis. It has also been 
found that Treg cells can suppress the function APCs and thus indirectly block the 
activation of T cells.
[45]
 This latter mode of action has been attributed to the action of 
cytotoxic T lymphocyte-4 (CTLA-4), a membrane-bound competitor of CD28 for B7 
molecules on APC. CTLA-4 binds B7 molecules about 20 times more avidly than does 
CD28 and delivers an inhibitory signal to the activated T cell.
[46]
 Efficacy of mAb 
blocking this negative co-stimulator has been demonstrated in mouse models of various 
tumors and are being evaluated in phase III clinical trials. .
[47]
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    It has been postulated that Treg cell-mediated immunosuppression promotes tumor 
growth by changing the functions of CD8+ cytotoxic T cells and NK cells operating in 
tumors. 
[40, 42, 48, 49]
 It has been suggested as a factor to explain the sub-optimal clinical 
responses of active tumor immunotherapy, including various formats of vaccines.
[48]
 Data 
from Valzasina et al.‟s work demonstrate that the number of CD4+CD25+ T cells has 
been increased in draining lymph nodes and the spleen of tumor-bearing mice.  In that 
study, about 10-15% of CD4+ T cells were found bearing the CD25 marker in draining 
lymph nodes and the spleen of tumor-free mice. Whereas this level increased to 22-30%, 
even to 40% as the highest in tumor-bearing mice.
[41]
 Thereafter, a higher frequency of 
Treg cells in peripheral blood was reported in patients with various cancers including 
non-small-cell lung cancer, breast cancer, ovarian cancer, pancreatic cancer, etc. These 
studies demonstrated that peripheral Treg cells possess suppressive activities thereby 
comprise anti-tumor immunity in cancer patients.
[40, 49-52] 
    Based on these results, it was predicted that removal of Treg cells from tumors and 
tumor-draining lymph nodes would unveil a strong antitumor immunity. Monoclonal 
antibodies targeting to the surface molecules of Tregs have been found, in some cases, to 
reverse Treg-dependent tumor immune-tolerance.
[40, 42]
 In vivo administration of CD4 or 
CD25-specific antibodies have been found to induce effective tumor rejection in murine 
tumor models. Concomitantly, dramatic increases of CD8+ T cells and INF-γ production 
were detected inside the tumor after CD4+ T cell depletion. 
[6, 53]
 In the study done by 
Coe et al. demonstrated that Treg cells constitutively expressed higher level of 
glucocorticoid-induced tumor necrosis factor receptor (GITR), a member of the TNF 
receptor family, than conventional T cells. A single injection of DTA-1 (anti-GITR mAb) 
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resulted in the regression of established solid tumors. It was also showed that the 
regression of tumor by anti-GITR mAb therapy was correlated with increased 
accumulation of tumor-infiltrating CD4+ (17% compared to 3% in untreated group) and 
CD8+ (22% compared to 4% in untreated group), but decreased accumulation of Treg 
cells (0.4% compared to 1.2% in untreated group).
[54]
 
   Several of the mAb are on the market, for example daclizumab (Roche), a CD25-
specific agent, and tremelimumab (Pfizer) and ipilimumab (Bristol-Myers Squibb), 
CTLA4-specific agents.
[2] 
These antibody-based treatments have been proved to be 
effective to enhance adaptive immunity and promote tumor regression. However, clinical 
outcomes are limited by nonspecific depletion of effector T cells, and in many cases, 
systemic autoimmune side effects. Thus these antibody-based approaches are limited. 
Moreover, the tumor mass is not amenable to the penetration, distribution and 
accumulation of antibodies. It is acidic (pH~6), increasing the likelihood of antibody 
denaturation. The elevated pressure (due to microvascular hypertension) resulting from 
extravasated fluids causes an outward convective current, moving macromolecules out of 
the tumor.
[55]
 Collectively these factors call for new strategies in using anti-T cell 
antibodies. The ability to capture CD4+ T cells and alter their phenotypes in vivo could 
be developed into a new type of immunotherapy.  
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BETA STRUCTURE-BASED SELF-ASSEMBLING PEPTIDE SCAFFOLDS 
    In the past decade, many studies have focused on the design and use of self-assembling 
peptides as biological scaffolds. These peptides share a common feature of self-
association in aqueous solutions. They are either fragments of natural proteins or derived 
by de novo biomolecular design. Within the biomaterials community, molecular self-
assembly is, defined as spontaneous organization of molecules under near 
thermodynamic equilibrium conditions into structurally well-defined and stable 
arrangements through noncovalent interactions.
[56] 
Such interactions typically include 
hydrogen bonding, electrostatic and van der Waals interactions. The first member of the 
family which has the sequence Ac-(AEAEAKAK)2-NH2, commonly referred to as 
“EAK16” or “EAK-II”, (now termed “EAK” here), was discovered in the yeast Z-DNA 
binding protein Zuotin.
[9, 10]
 EAK contains repeats of alternating polar and nonpolar 
residues and repetitive pattern of positive and negative charges (figure 3-2 a).  These 
physical properties provide the mechanisms for intermolecular complementarities of 
hydrophobic and ionic interactions. 
 Proposed self-assembly mechanism 
    EAK contains tandem repeats of alternating hydrophilic and hydrophobic residues, in 
which every other residue in the peptide is alanine. At neutral pH, the four glutamic acids 
and four lysines are negatively and positively charged, respectively. In deionized or low 
ionic water, EAK forms stable β-sheets in which the polar and non-polar side chains 
orient to opposite sides (figure 3-2 b). Resulting is a structure in which the charged side 
chains lie on the same side and all alanine side chains are oriented on the opposite side. 
Upon exposure to salt solution, these amphiphilic β-sheets spontaneously stack up by 
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inter-strand pairing of charged residues (glutamate and lysine) and hydrophobic 
interactions of alanines (figure 3-2 c).
[10, 57-59]
 Stacks of fibrous oligomers (7-20 in 
diameter) interweave to form macroscopic membrane-like structures (figure 3-2 d and 
e).
[10, 57]
 Once formed, these macroscopic structures acid and protease-resistant, and 
remains intact at temperature up to 90°C.
[11]
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Figure 3-2: Schematic structures of EAK and EAK nano-structure. (a) 
chemical structure of EAK, (b) a single β-sheet formed from two molecules of 
EAK16, (c) a perpendicular staggered β-sheets, (d) stacking of β-sheets. The 
staggered peptides are oriented along the x axis. The z axis has the 
complementary ionic bonds between lysine and glutamic acid, as well as the 
hydrophobic bonds between alanines. The y axis contains the conventional β-
sheet hydrogen bonds.[10] (e) nanofibers cross-linked to form the membrane. 
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 Salt effect on the self-assembly 
    Zhang and coworkers further studied the effects of salts on the spontaneous-assembly 
process.
[10, 56]
 It was observed that only monovalent cations are most effective in inducing 
assembly formation. The order of effectiveness has been determined as Li
+
>Na
+
>K
+
>Cs
+
, 
which is consistent with the hydrated radius of the ions: 3.4Å (Li
2+
), 2.8Å (Na
+
), 2.3Å 
(K
+
) and 2.3Å (Cs
+
). Divalent cations on the other hand induce disordered aggregation, 
rather than ordered periodic structures.  NH4
+
 and TrisHCl are not able to induce EAK 
to form aggregates. It is an indication that the metal ions are more likely the components 
of the peptide structure, rather than as a catalyst only stabilizing the electronic charges. 
The salt-induced process is thought to be driven by charge screening by monovalent 
cations between the basic and acidic side chains on peptide molecules, resulting in 
decreased electrostatic repulsion. This however does not explain the differential effects of 
monovalent and divalent ions. A unifying perspective is that the spontaneous process is 
driven by free energy gained from entropic release of water molecules structured around 
the alanines into the bulk solution as two β-sheet stack upon one another at high 
concentrations.
[60] 
When multiplied throughout many alanines in the system a significant 
amount of energy can be derived, making the process a spontaneous one. In this scenario 
the charged side chains reduce the entropic gain in free energy by decreasing the 
orderness of bound waters around alanines. The addition of monovalent and small ionic 
species dislodges the charged side chains from the alanine salvation spheres thereby 
allowing maximal orderness of water molecules surrounding the hydrophobic moieties.
[61]
 
The precise role of salts, however, remains under investigation.  
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Concentration effect on the self-assembly 
    Both Fung et al.
[62]
 and Hong et al.
[63]
 reported that there is a critical self-assembly 
concentration (CSAC), which is 0.1mg/ml (60μM) for EAK in pure water. Surface 
tension and self-assembled nanostructures formation were determined for a wide range of 
peptide concentrations using an axisymmetric drop shape analysis-profile (ADAS-P) and 
atomic force microscopy (AFM). The principle of the analysis was that changes in 
solution properties associated with molecular aggregation could be measured. A “break 
point”, or minimum, is observable in the surface tension corresponding to the CSAC. 
AFM studies revealed that EAK formed fibrillar networks above the CSAC, while 
isolated filaments were observed at concentrations below the CSAC.  The implication of 
these results is that mechanical properties of the assembly can be tuned by varying the 
concentration of the peptides in the system.                
pH effect on the self-assembly 
    While interactions among the charged amino acids in EAK may not initiate stacking of 
β-sheets, they must contribute to the stability of the insoluble structures through 
electrostatic interactions. The ionization state of the four lysines and four glutamic acids 
in EAK can be tuned by pH in the environment, with all ionized at neutral pH. EAK 
contains four positively charged lysine and four negatively charged glutamic acid 
residues at neutral pH. In the aqueous environment, lysine has an estimated pKa of 10 
and glutamic acid has an estimated pKa 4.4, with EAK having a calculated isoelectric 
point (pI) of 6.7. It was predicted that changes in pH would greatly affect the β-sheet 
structure of EAK. These effects have been studied systematically. Using circular 
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dichroism (CD), Zhang et al. reported a stable β-sheet structure for EAK from pH 1.5 to 
11.
[11]
 AFM images of EAK at various pH values indicated fibrillar nanostructures 
formed throughout the pH range from 4 to 11.
[64]
 Given the purported configuration of 
the self-assembly, it is unexpected that no significant changes of EAK structures were 
registered. Such resistance to acidic and alkaline conditions is likely due to the 
complementary ionic bonds or hydrogen bonds between glutamic acid and lysine when 
EAK exists in the β-sheet form. Protonated and deprotonated carboxylic acids and amines 
may remain hydrogen bonded. Since the β-sheets are staggered and overlaid, the 
collective interaction energy should be much greater in for individual β-sheets. The 
additive interactions within the multilayer aggregate most likely cause the unusual 
stability.
[56, 64]
 
Design rationale for self-assembling peptides 
     The sequence dependence of self-assembling peptides motivated the design of novel 
structures by changing the amino acid compositions. Assumed to be relatively low in 
immunogenicity and good biocompatibility, such sequences have been used mainly as 
scaffolds for tissue engineering in regenerative medicine and controlled drug release 
systems. Among these are peptides that are classified based on ionic complementary 
typed moduli (modulus I, modulus II, modulus III, modulus IV, etc., and mixtures 
thereof). This classification scheme is based on the pattern of alternating positively and 
negatively charged amino acids separated by one, two, three residues, and so on. For 
example, charge arrangements for modulus I, modulus II, modulus III, and modulus IV 
are − + − + − + − +, − − + + − − + +, − − − + + +, and − − − − + + + +, respectively.[57, 58] 
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Therefore, the first EAK peptide with the sequence Ac-(AEAEAKAK)2-NH2 is termed as 
EAK16-II. 
    Xiong et al. claimed that in self-assembling oligomeric peptides the polar/nonpolar 
periodicity could overwhelm the intrinsic propensities of amino acid residues, serving as 
the major determinant of peptide secondary structure.
[65] 
Extending this notion, Zhang et 
al. hypothesized that if the charged residues in EAK are substituted with other amino 
acids with the same charge (i.e., Glu−>Asp or Lys−>Arg in the reversed EAK sequence) 
or hydrophobic residues with other hydrophobic amino acids (Ala−> Phe or Ala−> Leu), 
there would be essentially no drastic effects on the self-assembly process. 
[65, 66]
 
    To test this hypothesis, another set of self-assembling peptides containing the RAD 
sequence, a similar motif found in EAK  was characterized.  These include RAD16-I, Ac-
(RADARADA)2-NH2, and RAD16-II, Ac-(RARADADA)2-NH2. Indeed, RAD16-I has 
been comercially produced as PuraMatrix from BD Biosciences (MA, USA)
. [67]
     
Application of RAD16-I in controlled drug release 
    Because of the small diameter of peptide nanofibers (~10nm), nanofibers gels have a 
high surface:volume ratio compared to biopolymers with larger diameter fibers. This high 
surface ratio permits the adsorption of large quantities of drugs. 
[68] 
    Zhang et al. examined RAD16-I as matrices for controlled drug release. Microscopic 
images revealed that the peptide self-organizes into interwoven nanofibers with diameters 
of 10-20nm. These nanofibers further associate to form highly hydrated hydrogels (up to 
99.5% w/v water), with pore size between 5 and 200 nm in diameter.
[57, 69]
 The group  
reported that RAD16-I can be used to control the release of small molecules.  Phenol red, 
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bromophenol blue, 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine, 3-
PSA), 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt (4-PSA), and Coomassie Brilliant 
Blue G-250 (CBBG)) (figure 3-3) released through 5% w/v RAD16-I hydrogels were 
investigated. The mass-transfer kinetics for the release of the dyes were illustrated with 
mass released fraction (Mt/M∞) monitored as a function of time (t). Phenol red, which is 
presumed to have no electrostatic interactions with the peptidic nanofibers, was released 
quickly; more than 50% of the loaded amount was released after 2 h and reached a 
plateau after 12 h. Although bromophenol blue has molecular structure similar to phenol 
red, it is not readily released from the matrices. Bromophenol blue has a lower pKa (4) 
than phenol red, which has a pKa of 7.9. Hence, the phenolic hydroxyl group of 
bromophenol blue tends to dissociate at neutral pH and thereby can interact strongly with 
the positively charged amines of the arginine residues in RAD16-I. Even after 7 days, 
bromophenol blue was essentially retained in the peptide scaffold. The mass fraction 
(Mt/M∞) of release for 3-PSA and 4-PSA reached 26% and 9% after 7 days, respectively. 
Additionally, the diffusivity of 3-PSA was approximately seven times higher than that of 
4-PSA. The difference in the release rate is most likely due to electrostatic interactions 
between the sulfonic acid groups and the positively charged amine groups of the peptide 
nanofibers. 4-PSA has 4 sulfonic side groups while 3-PSA only has 3. As CBBG binds 
strongly to proteins, it is concluded that this interaction impedes its release from the 
RAD16-I matrices. 
[69]
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Figure 3-3: Molecular structure of the model drugs: (a) phenol red, (b) 
bromophenol blue, (c) 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (3-
PSA), (d) 1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt (4-PSA) and (e) 
Coomassie Brilliant Blue G-250 (CBBG).[69] Reprinted, with permission, from © 
2006 Elsevier B. V.: [Journal of Controlled Release] (Vol.115 Page19, 2006).  
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     Subsequently, the same group tested a series of proteins as model encapsulated drugs 
to study the kinetics of release from RAD16-I peptide hydrogel.
[70]
 These include 
lysozyme, trypsin inhibitor, bovine serum albumin, and IgG, proteins with differing 
physicochemical properties (pI 4.6-11.4; molecular mass, 14.3-150kDa) and 
morphologies (listed in Table 3-1). The results showed that the peptidic matrix appeared 
to be a robust system for sustained release of proteins in aqueous environments. IgG has 
the slowest release among the proteins tested, with measurable concentration detectable 
only after 60 h. As expected, it was found that large proteins were retained inside the 
matrix for longer periods compared to smaller proteins, as in the case for most other 
fibrous matrices.
[68]
 The implication being that the rate of release is more sensitive to 
physical size than charge. Lysozyme, the smallest (radius ~1.9nm) among the proteins 
studied, was released fastest. Trypsin inhibitor, which is slightly larger and oppositely 
charged compared to lysozyme, was released slower than lysozyme but faster than bovine 
serum albumin, a larger protein. Conversely, the release rates do not correlate with the 
isoelectric points of the proteins. The data also indicate that increasing the peptide 
concentration results in a higher density of nanofibers in the network, which could hinder 
the release of the proteins. Therefore, protein release through the RAD16-I can be 
controlled by varying the peptide concentration. In examining the functionality of the 
protein released, identical circular dichroism (CD) spectra and similar activity values 
were obtained for proteins recovered compared to the freshly prepared native proteins. 
Hence, it can be concluded that the encapsulation process and release mechanisms do not 
affect integrity of the proteins studied. 
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Protein Molecular mass 
( kDa) 
Hydrodynamic radius  
(nm) 
pI 
Lysozyme 14.3 1.9 11.4 
Trypsin inhibitor 20.1 2.4 4.6 
BSA 66.0 3.6 5.3 
IgG ≈150.0 5.3 ≈7.2 
 
Table 3-1: Physicochemical properties and morphologies of the model 
proteins.[70] 
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Immunogenicity of RAD and EAK peptides 
    Zhang et al. attempted to produce antibodies using RAD16-II and EAK oligopeptides. 
However, when these peptides were either alone or conjugated with other proteins and 
injected into rabbits, they did not elicit a detectable immune response, and no significant 
titers of antibodies were obtained.
[61]
 It was found that these peptides had a similar amino 
acid sequence as a segment in intermediate neural filament H, L and M proteins.
[71]
 These 
sequence similarities may cause the lack of immunogenicity.  Holmes et al. injected EAK 
and RAD (including RAD16-I and RAD16-II) peptides into the rats leg muscles to test 
for their induction of inflammation. The rats were killed 9 days or 5 weeks after the 
injections. The entire muscle was dissected and sectioned. The muscle sections were then 
stained with Nissl and thionin (specific for ribosomal RNA) and examined by using light 
microscopy for mononuclear cell infiltration and muscle fiber necrosis for signs of 
inflammation or necrosis. No apparent inflammation or any structural abnormalities were 
observed in the muscles that were injected with either saline or the peptides.
[12]
 A 
collection of these results indicates that these self-assembling peptides are non-
immunogenic, which is important so as to reduce immune rejection if these peptides are 
developed for tissue engineering or in vivo drug delivery. 
In vivo application of RAD16-II in protein delivery      
    Lee et al. have investigated RAD16-II for myocardial protein delivery. 
[68, 72-74]
 In one 
application, platelet-derived growth factor (PDGF) was bound to RAD16-II non-
covalently and resulted sustained delivery (~2 weeks) of the growth factor when the 
construct was injected into infarcted rat myocardium. After myocardial infarction, this 
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local protein therapy improved cardiac function, decreased cardiomyocyte apoptosis, and 
decreased infarct size.
[72]
 This group also attached biotin to RAD16-II, and formed the 
biotinylated hydrogel by using 1:100 biotinylated peptides/nonbiotinylated peptides. 
Insulin-like growth factor 1(IGF-1) was then biotinylated as well and tethered to the 
peptide hydrogel with the aid of tetravalent strepavidin (figure 3-4). IGF-1 is a small 
protein that diffuses readily through tissues, a property that allows it to signal over great 
distances, but could restrict its retention within a tissue for prolonged periods. This biotin 
sandwich method is designed to deliver IGF-1 with biotinylated peptides to maximize the 
probability of peptide self-assembly and thus retention in the myocardium. After injection 
into rat myocardium, this “biotin sandwich” approach provided sustained IGF-1 delivery 
for 28 days, compared to 3 days for untethered IGF-1.
[73]
 In order to incorporate protein 
stably into nanofibes, fusion protein was also made. For instance, this group constructed a 
fusion protein consisting of the stromal cell-derived factor-1 (SDF-1) sequence and the 
RAD16-II sequence, referred as SDF-1-RAD. SDF-1 is a potent chemoattractant for 
endothelial progenitor cells. Injected with a mixture of RAD16-II and SDF-1-RAD, the 
infarcted zone showed improved cardiac function and capillary density. 
[74]
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Figure 3-4: Schematic showing the biotin sandwich method: Tethering 
biotinylated IGF-1 (b-IGF) to biotinylated self-assembling peptides by using 
tetravalent strepavidin.[73] Reprinted with permission from ©2006 The National 
Academy of Science of the USA: [PNAS](Vol.103 Page 8156, 2006). 
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   Design of KLD12 and its application in cell culture 
     In addition to the classical 16-mer peptides, smaller self-assembling sequences, 
including KLD12, Ac-(KLDL)3-NH2,  have also been designed and tested.
[75]
 Recall that 
the principal forces of the self-assembly are ionic complementary and hydrophobic 
interactions. It was subsequently determined that the proportion of hydrophobic residues 
in the sequence significantly influences the mechanical properties of the scaffolds and the 
speed of self-assembly
[75]
. The more hydrophobic the sequence, the shorter the length is 
required for aggregate formation with stronger mechanical properties. KLD12 was thus 
designed on the basis that leucine is more hydrophobic than alanine, and therefore more 
likely to pack tightly in the nanofibers in aqueous conditions, resulting in higher 
mechanical strengths.
[75, 76]
 Grodzinsky et al. characterized KLD12 as a 3D scaffold for 
encapsulation of cells. Chondrocytes seeded within the KLD12-I matrix retained their 
morphology. The cell-peptide composite developed a cartilage-like extracellular matrix 
(ECM) rich in proteoglycans and type II collagen, indicative of a stable of chondrocyte 
phenotype. The results demonstrated the potential of KLD12-I as a scaffold for the 
synthesis and accumulation of a cartilage-like ECM within a three-dimensional call 
culture for cartilage tissue repair.
[76] 
This peptide was also tested with bone marrow 
stromal cells (BMSCs). Only cells seeded with the peptide matrix but not agarose yielded 
high glycosaminoglcan content, spatially uniform proteglycan and collagen type II 
deposition (all indicating for cell proliferation).
[77] 
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 Design and application of β-hairpin peptides 
   Another configuration for assembly is a design through β-hairpin. In this conformation 
two adjacent strands in an oligopeptide oriented in an antiparallel arrangement are linked 
by a short loop of two or five amino acids, shaped as a hairpin. Schneider and Pochan 
have developed a set of β-hairpin peptides that self-assemble into rigid hydrogels.[78-84] 
These peptides contain a pair of turn inducing residues such as proline followed by 
glycine or threonin. The cyclic structure of proline causes a slight kink in the α-carbon 
backbone and in combination with the more comformationally flexible glycine or 
threonine residues that follow allows a complete reversal of the direction of the α-carbon 
backbone. The loop is cemented by the two residues before and after the turn-inducing 
pair and subsequent residues to hydrogen bond together, holding the peptide strand into a 
tight hairpin. Non-natural D form of proline is used in the turn sequence to permanently 
force a type II’ turn and prevents a cis-proly bond that could create heterogenicity in the 
unfolded population of peptides (figure 3-5 a).
[79]
 A prototype of these is “MAX1” (figure 
3-5),
[80]
 which contains a total of 20 amino acids with alternating valine (V) and lysine (K) 
residues on two β-strands connected by a tetrapeptide (-VDPPT-) sequence. These 
peptides are designed to remain freely soluble and unfolded due to electrostatic 
repulsions between the positively charged lysine side chains at neutral pH. When a 
physiologiacally relevant salt concentration is introduced, the electrostatic repulsions 
between the lysine side chains are screened and the peptide folds into a β-hairpin 
structure, stabilized by intramolecular hydrogen bonds. When folded, the hairpin exhibits 
facial amphiphilicity and the valine-rich face undergoes hydrophobic collapse, driving 
the self-assembly of the folded hairpins into fibrils. The β-hairpin peptidic gels are 
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cytocompatible with mammalian cells, including fibroblasts, mesenchymal stem cells, 
primary articular chondrocytes, and hepatocytes.
[78, 81]
 Cells can be encapsulated during 
self-assembly, resulting in cells being homogeneously distributed throughout the fibrillar 
network. In addition, these peptide hydrogels possess the ability to shear thin and recover, 
allowing the gel-cell constructs to be delivered via syringe. 
[78, 82]
 
    The Schneider series and other amphiphilic peptides demonstrate a key feature: it is 
possible to tailor matrices to specific biomedical applications through unique 
arrangements of secondary structures by careful selection of amino acids. This flexibility 
drives the imagination of designing capabilities for self-assembling structures. In addition 
to those already discussed, several other systems warrant mentioning. Peptide P11-4 (Ac-
QQRFEWEFEQQ-NH2) was designed by Aggeli et al. to self-assemble to form β-sheets 
and nematic gels in the pH range 5-7 at concentrations ≥12.6 mM in water. This self-
assembly is reversibly controlled by adjusting the pH of the solvent. A peptide P11-3 (Ac-
QQRFQWQFQQQ-NH
2
) whose self-assembly behavior is independent of pH was first 
designed. pH control was then incorporated by appropriately positioning glutamate (E) 
side chains so that the peptide-peptide free energy of interaction in the tapelike 
substructure was strongly influenced by direct electrostatic forces between COO
-
 in 
glutamate.
[85, 86] 
Collier and Messersmith described a similar peptide, Ac-
QQKFQFQFEQQ-NH2, which exists as β-sheets and self-assembled into fibrillar 
aggregates. The resultant structures contain several pendant glutamine residues that can 
be cross-linked with lysine containing peptides in the presence of transglutaminase and 
calcium ions.
[87]
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Figure 3-5:  Schematic of β-hairpin peptide assembly. (a) Sequence and 
proposed β-hairpin structure of peptide MAX1. Alternate folding/self-assembly 
pathways dependent on turn structure contained within MAX1. Valine at position 
9 strongly enforces a trans-prolyl amide bond geometry favoring hairpin 
formation prior to self-assembly (pathway a). A cisgeometry, which is designed 
against, may result in an extended conformation, which could undergo mixed 
self-assembly with correctly folded hairpins (pathway b). [79] Reprinted with the 
permission from © 2002 American Chemical Society: [Journal of the American 
Chemical Society] (Vol. 124, Page15031, 2002) (b) Proposed mechanism for the 
folding and self-assembly of β-hairpin hydrogels.[80] Reprinted with the 
permission from © 2008 Elsevier Ltd. [Biomaterials] (Vol. 30, Page 1340, 2009). 
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    Taken together, synthetic self-assembling peptides have tremendous potential as 
biomaterials because they can be readily modified at the amino acid level. The responsive 
to stimuli, for example ionic strength and pH, is a major advantage in developing in vivo 
applications by designing around one or more physiological condition(s). The peptides 
appear to be non-immunogenic, and the matrices can be loaded with biologically active 
proteins for prolonged release. 
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CHAPTER 4 
PHYSICAL CHARACTERIZATION OF EAK-EAKH6 COMPOSITE 
 
INTRODUCTION 
     Both naturally occurring and synthetic materials have been used for protein delivery. 
Naturally occurring materials include collagen, gelatin, agarose, alginate, chitosan, etc. 
The advantage of naturally occurring materials is their known physiological activities, 
mechanical properties, and biodegradability. These materials may also be relatively 
inexpensive. However, potential transfer of infectious agents from animals, antigenicity 
and unstable material supply are potential disadvantages. Moreover, specific properties of 
naturally derived materials that are necessary for protein delivery are difficult to design. 
Synthetic polymers can be produced on a large scale, and their structural and mechanical 
properties can be more easily modified. Commonly used materials are polylactide (PLA), 
glycolide-lactide copolymer (PLGA), polyvinyl alcohol (PVA), and poly-ethylene glycol 
(PEG). Potential disadvantages of synthetic polymers are a decrease in local pH from 
acid breakdown products, bulk degradation, and inflammatory responses. 
[68]
 
    In the past decades, self-assembling peptides have been developed for tissue 
engineering and protein delivery. These peptides recently attracted intense research 
interests because they are injectable, non-immunogenic, biocompatible, and flexible in 
design and modification.
[56, 57, 88]
 The first member of this class of self-assembling 
peptides is EAK. Discovered in the sequence of the yeast Z-DNA binding protein zuotin, 
EAK (also referred to as “EAK16-II” in the literature) is prototypical of a class of self-
assembling peptides characterized by periodic repeats of alternating polar and non-polar 
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amino acids. In water, EAK adopts a β-sheet conformation. In buffers containing 
monovalent metal ions (Na
+
, K
+
), the peptide assembles into an ordered stable quaternary 
β-sheet structure. This high molecular weight assembly is resistant to proteases, high 
temperature (up to 90°C) and acidic or alkaline conditions (pH 4-11). 
[9-11]
 
    The EAK assembly has been used as a scaffold for promoting cell growth in vivo.  
Cells co-injected with the EAK peptide form cell-embedded matrices with biological 
functions. Such applications in tissue engineering represent a form of individualized 
medicine mostly practiced in academic settings. An “off-the-shelf” injectable capable of 
modulating host cells in vivo would have much wider applications. 
[58, 61]
 
    The goal of this project is to develop a platform technology by introducing a His-tag 
onto the insoluble structure as “mounting sites”. This was done by seeding into the 
assembly with EAKH6, which contains six histidines at the C terminus of the EAK 
sequence. It was hypothesized that the amphiphilic domain (AEAEAKAK)2 intercalates 
into the EAK β-sheets, with the C-terminal his-tag domain extruding out-accessible as 
binding sites. The assumption is that the histidine appendage does not interfere with the 
ability of the amphiphilic domain to engage the same in EAK oligomers in macroscopic 
insoluble structures.   
     This chapter describes preparation and characterization of assemblies made with EAK 
and EAKH6. The goal is to demonstrate the integration of EAKH6 into the EAK -sheet 
network using analytical and biochemical means. It provides physical evidence on which 
subsequent functionalization is based. Four techniques were used to characterize the 
EAK-EAKH6 composite: UV-Vis, circular dichroism (CD), Fourier transformed infrared 
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spectroscopy (FTIR) and an enzymatic reaction using nickel-bound horseradish peroxide 
(HRP-Ni) as a probe of the H6 domain. Collectively, results from these analyses show 
evidence for EAKH6 integration into the EAK network. 
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MATERIALS AND METHODS: 
Peptide assembly preparation 
    The peptides EAK and EAKH6 were custom synthesized by EZBiolab (Carmel, IN, 
USA) custom synthesis service. The purities of EAK and EAKH6 are 79.54% and 
92.72% respectively. The peptides were acetylated at the N-termini and amidated at the 
C-termini to be chemically inert. Their identities were confirmed by mass spectroscopy. 
Upon arrival, the lyophilized peptides were reconstituted in sterile deionized water (18.2 
MΩ at 25°C) at a concentration of 3.13mM (5mg/ml for EAK and 7.8mg/ml for EAKH6) 
and stored at -80°C until use.  The peptide sequences are showed in figure 4-1. 
    To form the assembly, the peptides were thawed out. 10-20μl of the stock solution of 
EAK, or the mixture of EAK and EAKH6, was injected into 1.0 ml of phosphate buffered 
saline (PBS; 154 mM sodium chloride, 5.5 mM sodium phosphate dibasic, 1.2 mM 
potassium phosphate monobasic; pH 7.4; no calcium or magnesium). 2-4μl 0.1%(w/v) 
Congo red, which is the dye binding to β-sheet specifically, was added to visualize the 
structure. 
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Figure 4-1: Amino acid sequence of EAK and EAKH6. Peptides are 
acetylated and amidated at the termini. 
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UV-Vis analysis  
    The UV absorbance of peptide bond has been determined to investigate how much 
percentage of EAKH6 can be incorporated into the EAK fibrillar structure. The samples 
were prepared as follows: 10µl of the stock solution of EAK peptide (5mg/ml) was mixed 
with 1µl of the stock solution of EAKH6 (7.8mg/ml) peptide.  This mixture was added 
into 1ml PBS to initiate the structure formation. After that the sample was centrifuged at 
16,000×g force for 20 min to spin the peptide assembly down. The supernatant was 
collected and absorbance at 205 nm was measured on a Lambda35 UV/Vis Spectrometer 
(PerkinElmer Instruments, Shelton, CT, USA). Meanwhile the groups of 50 µg of EAK 
and 7.8µg of EAKH6 by themselves were incorporated as well. 
Fourier transform infrared spectroscopy spectroscopy 
    FTIR spectra were recorded on a Thermo Nexus 470 Infrared Spectrometer operated at 
a spectral resolution of 0.5 cm
-1
 over 1024 scans. Fibillar structures were formed in PBS 
(1ml) with 100μg EAK, or the same amount of EAK with 78μg EAKH6 for the 
composite. After centrifugation (16,000×g for 20min using an Eppendorf 5415R 
Centrifuge), the supernatant was removed and the structure was washed to remove 
unbound EAKH6. The fibrillar structure collected was then lyophilized by a Labconco 
Freeze Dry System/Freezone 4.5 prior to FTIR analysis under inert condition and 
scanned over 400-4000 cm
-1
. 
Circular Dichroism (CD) measurement 
    CD spectra were obtained on a Jasco J-810 spectropolarimeter (Jasco Analytical 
Instruments, Germany) with Jasco‟s Spectra ManagerTM software for data processing.  
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Spectra were recorded from 190 to 250 nm at room temperature by accumulating 10 runs. 
After correction for solution blanks, absorbance values were converted to mean residue 
ellipticities according to the equation 4-1: 
             

[]
100obs
cnl
                  Equation. 4-1 
Where θobs denotes the measured ellipticity, c the peptide concentration in mM, n the 
number of amino acid residues, l the path length of the quartz cuvette in cm. Finally the 
θobs was plotted against the wavelength using Excel 2007(Microsoft, USA). The 
secondary structure conversion of EAKH6 was evaluated by the comparing the CD 
spectra of EAKH6 by itself and the EAKH6 component in the mixture with EAK. 
Furthermore, the analysis of secondary structure composition has been performed using 
CD Pro software, which contains three popular methods (SELCON3, CONTINLL and 
CDSSTR) for CD analysis. The software is available at the website: 
http://lamar.colostate.edu/~sreeram/CDPro/main.html. A reference set containing 43 
soluble proteins was chosen to execute the programs. 
Nickel conjugated horseradish peroxidase (HRP-Ni) binding assay 
    HRP-Ni is a nickel (Ni
2+
) activated derivative of horseradish peroxidase (HRP) used 
for direct detection of poly-histidine tagged proteins since nickel can form coordination 
interaction with histidine side chains. HRP-Ni was obtained from Pierce (IL, USA) as 
lyophilized powder. Upon arrival, the enzyme was reconstituted in sterile ddH2O at a 
concentration of 4mg/ml, and stored at -80°C until use.  
    The peptide assembly was formed by injecting a mixture of 50μg EAK and 19.5μg 
EAKH6, mole ratio 1:4 (EAKH6: EAK), into 1ml PBS. The groups of individual 50μg 
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EAK and 19.5 μg EAKH6, and equal volume of PBS were included as well. 1μl of 
0.1%(w/v) Congo red was also added to visualize the structure. After the membrane-like 
structure was formed, 1μl of 0.8μg/ml (1:5,000 dilution of the stock) HRP-Ni was added 
into each sample. The mixtures were incubated on ice for 1 hour. Then the samples were 
centrifuged at 16,000×g for 20 min to spin the assembly down. The supernatants were 
taken out and filtered through a 0.22μm filtered to remove any insoluble fragments. 100μl 
of the filtrate was mixed with 100μl of TMB substrate (BD Biosciences, CA, USA) in 
96-well plate. Triplicates were done for each sample. The plate was incubated for 30 
minutes at room temperature in the dark. Afterwards, 50μl stop solution (2N H2SO4) was 
added to each well, and the plate was read for absorbance at 450nm. The results were 
corrected by subtraction of the absorbance at 570nm. All the absorbance was determined 
using a PerkinElmer wallac 1420 multilabel counter (PerkinElmer Life and Analytical 
Sciences, Finland).  A standard curve of HRP-Ni was also performed from serial dilution 
of 0.125ng/ml to 8ng/ml. The concentrations of unbound HRP-Ni in the supernatants 
were then calculated. 
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RESULTS AND DISCUSSION: 
Peptide assembly  
    EAK assembly can be prepared and visualized by injecting 10μl of the stock peptide 
solution (5mg/ml) mixed with 2μl 0.1% (w/v) Congo red into 1ml PBS. The insoluble 
structure is red, due to the binding of Congo red purported to bind to hydrophobic 
grooves in fibrous -sheet structures (figure 4-2 a).[10, 89] Figure 4-2c shows the self-
supporting nature of the assembly prepared by mixing equal volume of EAK (5mg/ml) 
and PBS. This suggests that the peptide molecules assemble into a 3-dimensional 
structure.  
    EAK-EAKH6 assembly was prepared from injecting a mixture of 50μg EAK and 
19.5μg EAKH6 into a volume (1ml) of PBS. The mixture produced an insoluble structure 
visually similar to EAK. On its own EAKH6 does not associate into aggregates as 
evidenced by the lack of Congo red binding (figure 4-2 b). Mixture of EAK and EAKH6 
also form a 3-dimensional gel-like substance, as evidenced in figure 4-2 d. 
    This result indicates that the spontaneous assembly of EAK is not disrupted by the 
presence of EAKH6 at 4:1 (EAK: EAKH6) mole ratio. However, formation of insoluble 
structure does not prove the existence of EAK-EAKH6 composite. The presence of the 
Congo Red-stained structure could be caused by self-assembly of EAK with EAKH6 
excluded and remained in the aqueous solution. Evidence will be presented in the 
following chapters to support the notion that EAKH6 is indeed integrated into the EAK 
network. 
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Figure 4-2: Formation of the peptide assembly. (a) Fibrillar structure formed 
from 50μg EAK was revealed by Congo red (1μg/ml) staining in 1ml PBS, but not 
in 1ml ddH2O, (b) Congo red staining of β-sheet-rich structures in PBS containing 
EAK, EAK-EAKH6 and EAKH6 by itself, and self-supporting structure of (c) EAK, 
(d) EAK-EAKH6 gel-like structure in an inverted vial. 
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Characterization of the fibrillar structure composition 
    The fraction of EAKH6 associated with EAK was determined indirectly based on 
quantity of peptides remained in the aqueous phase after centrifugation. At 16,000×g 
EAKH6 associated with the EAK fibrillar structure can be removed from the aqueous 
phase. The concentration of EAKH6 remained in the aqueous phase was determined 
using UV-Vis (absorbance by peptide bond at 205 nm) based on Beer‟s law (figure 4-3 
a). The results are summarized in figure 4-3 b. The difference between the mixture of two 
peptides and EAK alone is significantly lower than the equal amount of EAKH6 by itself. 
The percentage of EAKH6 incorporated into the fibrillar structure was calculated 
according to the equation 4-2. 
 
                                                                                                                        Equation 4-2  
 
    Based on the results from three independent experiments, 54.9±5.6% of the EAKH6 
was removed from the solution by centrifugation with the EAK assembly. The 
assumption here is that 100% EAKH6 on its own remain soluble and stay in the 
supernatant. These data indicate that more than half of the mixed EAKH6 can be 
incorporated into the network. This indirect measurement supports the fibrillar structure 
consists of both EAK and EAKH6.  
    UV-Vis absorbance assays are fast and convenient for determination of protein/peptide 
concentration, and do not consume the samples. Proteins in solution absorb ultraviolet 
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light with absorbance maxima at 280 and 190nm. Amino acids with aromatic rings, 
tyrosine and tryptophan, are the primary reason for the absorbance peak at 280 nm.
[90]
 
Since neither EAK nor EAKH6 contains these amino acid residues, the other strong 
absorbance by peptide bonds peaked at about 190 nm was used. Because of the 
difficulties caused by absorption by oxygen and the low output of conventional 
spectrophotometers at this wavelength, measurements are more conveniently made at 205 
nm, at which the absorbance is approximately half that at 190 nm. The advantage of 
using peptide bond absorbance is that there is little variation in response between 
different proteins/peptides.
[91]
 
    Based on the outcome of UV-Vis analysis, a major part of EAKH6 was centrifuged 
away from the supernatant in the presence of EAK. Since EAKH6 is soluble by itself, it 
must associate with the EAK structure and get precipitated out.  
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Figure 4-3: UV-Vis analysis of peptide aggregates. (a) Schematic of sample 
preparation, and (b) UV-Vis absorbance at 205 nm of the supernatants (n=3). 
The value of AEAK+EAKH6-AEAK is significantly lower than the value of AEAKH6 by 
one-tail t-test (p<0.01) 
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Chemical evidence of EAKH6 integration into EAK 
    The presence of the H6 domain in the EAK-EAKH6 composite was confirmed using 
FTIR spectroscopy (figure 4-4). The fibrillar structure was formed by injecting a mixture 
of EAK and EAKH6 (mole ratio 2:1, dissolved in water) into 1ml PBS, followed by 
centrifugation to remove unbound EAKH6. The aggregates collected were then 
lyophilized and subjected to FTIR scanning. The FTIR spectra of EAK-EAKH6 assembly 
and pure EAK were recorded and represented as percent transmittance as a function of 
wave-numbers (figure 4-4 a). Contribution of EAKH6 in the composite was obtained by 
subtracting the spectrum of EAK from that of EAK-EAKH6 (figure 4-4 c). 
     In figure 4-4 a, the spectrum of EAK-EAKH6 shows peaks in the 900-500 cm
-1
 
region, while there is no such peaks in the spectrum of EAK. Aromatic and 
heteroaromatic compounds display strong out-of-plane C-H bending and ring bending 
absorption bands in this region.
[92]
 The presence of EAKH6 in the EAK-EAKH6 
assembly can be evidenced by these bands in the aromatic ring vibration region since 
EAKH6 contains imidazole rings in its histidine side chains (figure 4-6b).  
    Figure 4-6 c shows the net contribution of EAKH6 in the mixed peptide assemblies. 
The presence of histidine is evidenced by the characteristics bands consistent with the 
chemical features of the imidazole ring (figure 4-6 c).
[92-94]
 Among these are peaks 
characteristics of stretching of the double bonds C4=C5 at 1529 cm
-1
. The peak at 3274 
cm
-1
 is assigned to the stretching vibration of C-H (C5-H and C2-H) in the imidazole 
ring.
[94, 95]
 A broad band centered at 1134 cm
-1
 is typical of the tautomeric forms of 
imidazole in the stretching of C2-N3 and C4-N3. The peak at 1051cm
-1
 represents C-H 
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bending at C4 and C5 of the imidazole ring. The peaks at 541 and 721 cm
-1
 are consistent 
with deformation vibration of ring structures, again supporting the presence of imidazole. 
Since the EAK sequence contains no ring structures, the composite must contain the H6 
domain. These spectroscopic results thus confirmed the presence of EAKH6 in the 
assemblies formed by a mixture of EAK and EAKH6. 
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  (a) 
(b) 
  
 
 
 
(c)  
 
 
 
 
Figure 4-4:  FTIR confirmation of EAKH6 in EAK-EAKH6 insoluble structure. 
(a) Fourier Transform Infrared (FTIR) spectra of lyophilized pure EAK and EAK-
EAKH6 insoluble structure, (b) chemical structures of EAK and EAKH6, and (c) 
Imidazole-specific peaks were assigned to spectra of EAK-EAKH6 subtracted 
with EAK. Peptides (dissolved in deionized water) were pipetted into 1ml PBS 
and collected by centrifugation (16,000×g for 20 min at 25°C). Samples were 
washed with PBS to remove weakly bound peptides not integrated into the 
assembly and subsequently lyophilized before scanning over 400-4000cm-1. 
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   Infrared spectrum is obtained when radiation in the range of 4000-400 cm
-1
 is absorbed 
and converted by an organic molecule into energy of molecular vibration. There are two 
main types of molecular vibrations: stretching and bending. The stretching frequencies 
are usually higher than corresponding bending because it needs more energy to stretch a 
bond than bend it. The two important areas for a preliminary examination of a spectrum 
are the regions 4000-1300 and 900-500 cm
-1
. The high-frequency portion of the spectrum 
is called the functional group region. This region tends to include motions, generally 
stretching vibrations, that are more localized and characteristic of the typical functional 
groups, e.g., O-H, C-H, N-H, found in organic molecules. Meanwhile the region of 900-
500 cm
-1
 involves usually molecular bending motions, which are characteristic for an 
aromatic or heteroaromatic structure.
[96]
 In the current system, the presence of imidazole 
ring in the EAK-EAKH6 composite can be confirmed by the peaks at 541,721 and 989 
cm
-1
.  
    The identification of a compound using IR spectroscopy relies heavily on the 
characteristic functional group frequencies. Certain groups of atoms give rise to bands at 
or near the same frequency regardless of the structure of the rest of the chemical 
environment. Based on this theory, the expectation is that the spectral contributions 
detected were only those of the poly-histidines by including the spectral signatures of the 
EAK as a background to be subtracted from the EAK-EAKH6 composite. In comparing 
to the spectrum of an authentic sample, most of the peaks in the subtraction spectrum 
match the characteristic peaks of histidine (i.e., C-H stretching at 3274 cm
-1
, C=C 
stretching at 1529 cm
-1
, C-N stretching at 1134 cm
-1
). The analysis is completed over 
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1024 scans and results are presented as an average of all 1024 scans, which strengths the 
case for sufficient background subtraction, and supports the strength of this evidence for 
EAKH6 presence in the fibrillar structure.  
    The IR spectroscopic analysis of the assemblies (collected by centrifugation) indicates 
that at least some of the added EAKH6 associated with the EAK assembly. One 
possibility is that the EAKH6 intercalates into the β-sheet stacks of EAK, thus becoming 
an integral part of the fibrillar structure. The other possibility is that EAK form the 
structure by itself with EAKH6 adsorbed physically, perhaps on the surface of the 
assembly. Neither UV-Vis analysis nor IR spectroscopy could offer mechanism of 
EAKH6 association with EAK. Thus further investigations to reveal the conformational 
change of EAKH6 when associate with EAK are warranted.  
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 EAK induces EAKH6 conformational change 
    For EAKH6 to integrate into the EAK β-sheets, the former must undergo a change in 
conformation. Circular dichroism (CD) was used to determine the dominant secondary 
structure of EAK, EAKH6 and EAKH6 in the presence of EAK (figure 4-5). The 
spectrum for EAK (figure 4-5 a) shows a broad negative maximum at ~216nm and a 
positive band near 200 nm, a profile consistent with a predominant β-sheet conformation. 
In contrast, the spectra of EAKH6 (figure 4-5 a) exhibits double minima at 206 and 
222nm, which are characteristic of α-helix conformation.[97] These spectra of individual 
peptide formed the basis of analyzing EAKH6 in the presence of EAK. 
    Mixtures of EAKH6 and EAK at mole ratios of 1:2 and 1:4 were also analyzed. 
Spectroscopic contribution by EAKH6 was determined by subtracting the contribution of 
EAK based on the spectrum of the pure peptide. This analysis indicates that EAKH6 
underwent conformational change from a predominant α-helix to contain β-strand 
conformation in the presence of EAK (figure 4-5 b).  
    The relative proportions of secondary structure compositions of the peptides were 
analyzed using the algorithms operated in the de-convolution program CD-Pro. The 
percentage of four secondary structure components, helix, strands, turn and random coil, 
were estimated by comparing with reference proteins from a database of 43 soluble 
proteins.
[98, 99]
 Figure 4-5 c shows the results of the analysis. EAK, as expected, adopts a 
high percentage of β-strand conformation at 58%, with the rest in turn and random coil. 
By itself EAKH6 exhibits a mixed secondary structures, containing 14~17% of β-strand 
and 24~28% of helix conformation. In the presence of EAK, however, the β-strand 
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fraction of EAKH6 increased to 86% at the mole ratio 1:2 (EAKH6: EAK), and 92% at 
1:4. Taken together, these data indicate that EAK induces EAKH6 undergo αβ 
conformational change at the microscopic level. It is consistent with the notion of 
integration of EAKH6 into EAK insoluble structure that consists of oligomerization of β-
sheets. 
    The pathway of EAKH6 association with the EAK structure was explored based on 
secondary structure composition. CD measures the differential absorption of the left and 
right circularly polarized components of plane-polarized radiation. This effect will occur 
when a chromophore is chiral, or optically active.
[97]
 All 20 natural amino acids, except 
glycine, possess a center of asymmetry at the α carbon atom. Hence different forms of 
regular secondary structure found in peptides and proteins exhibit distinct far-UV CD 
spectra at 180-250 nm, where the peptide bond is the chromophore. In solutions, EAK 
and EAKH6 adopted distinctly different conformations.    The basic principle involved in 
the analysis of CD spectra, and used in the estimation of secondary structure factions, is 
that the CD spectrum (Cλ) can be expressed as a linear combination of CD spectra of 
individual secondary structure components (k), Bkλ.  
    Equation. 4-3 
Where fk is the fraction of the secondary structure k.  This equation has been validated by 
Sreerama et al., in 2000.
[98]
 Spectra of model polypeptides or of a set of reference 
proteins with known structures are used to determine the component secondary structure 
spectra Bkλ. The secondary structure fractions for the reference proteins are determined 
from the corresponding crystal structure. The criteria to choose a reference set is based on  

C fkBk
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Figure 4-5: Conformational analysis of EAK and EAKH6. Spectra of EAK and 
EAKH6 in solution by itself (a) and net contribution of EAKH6 in the presence of 
EAK (b). Relative fractions of secondary structures in each were de-convoluted 
using CDPro (c). Data shown represents two independent experiments 
conducted. 
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the wavelength range and the nature of the sample peptides, native or denatured. 
Otherwise, a reference set with the largest number of proteins should normally be 
chosen.
[98, 99]
 Therefore, the secondary structure fractions analysis used a 43 soluble 
protein set, in which the work of Johnson et al., Keiderling et al., Yang et al., and 
Sreerama et al., was combined. 
[100-103]
  
    EAKH6 would most likely retain its helical conformation if it merely adsorbs onto the 
EAK structure. The CD analysis, however, reveals that EAKH6 undergoes αβ 
conformational change in the presence of EAK. The most likely cause for this change is 
that EAKH6 is integrated into the β-sheet stacks of EAK, forming complementary 
hydrophilic and hydrophobic interactions among glutamate/lysine and alanine, 
respectively.  
    The results further suggest that the higher the mole ratio of EAK to EAKH6, the more 
β-strand fraction in EAKH6. A possible explanation could be EAKH6 is much more 
dispersed in the matrix of EAK at higher mole ratio, and is forced to line up with the β-
sheets by the surrounding EAK molecules. Based upon the β fraction of EAKH6 at 
various mixing ratio (figure 4-5b), a mole ratio of 1:4 (EAKH6 to EAK) is sufficient to 
obtain almost 100% of the added EAKH6 integrated into the β-sheets of EAK. 
    It is likely that only the amphiphilic domain (AEAEAKAK)2 of EAKH6  intercalated 
into the β-sheets, with the non-complementary H6 domain extending from the EAK-
EAKH6 assembly. To prove this, an evaluation of the accessibility of H6 domain in 
EAK-EAKH6 composite is required.  
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EAK-EAKH6 composite displays H6 domains 
    A biochemical assay based on the enzymatic reaction of nickel conjugated horseradish 
peroxidase (HRP-Ni) was performed to determine the accessibility of H6 domains in the 
EAK-EAKH6 composite. HRP is an efficient enzyme which converts the substrate 
3,3‟,5,5‟ tetramethylbenzidine (TMB) into two-electron oxidation product, diimine, with 
the Km~3.6μM.[104] The reaction rate is coupled to colorimetric change.[104] Through 
nickel coordination HRP-Ni can bind to the histidines specifically.
[105]
 The assay was 
performed by incubating HRP-Ni with the assemblies. EAKH6 integrated into the EAK 
assembly should display the non-complementary H6 domains for binding with HRP-Ni. 
Assembly associated HRP-Ni can be removed by centrifugation (16,000×g) and filtration 
(0.22μm) from solution in which unbound HRP-Ni would remain. The amount of 
unbound HRP-Ni remained in the solution was quantified by the catalysis of TMB 
manifested in chromogenic change measured (λ=450nm). The amounts of free HRP-Ni 
were then calculated according to a standard curve relating observed optical density to 
known concentrations of HRP-Ni. The results are summarized in figure 4-6. The 
concentration of HRP-Ni in EAK-EAKH6 group was found significantly lower than the 
other groups by ANOVA and Tukey‟s multiple comparison tests, which suggested most 
of the HRP-Ni bound to the composite.  
    Results are normalized to samples HRP-Ni processed without any peptides, which 
represent the maximal possible amount of the enzyme remained in solution. Only 
7.8±4.5% of the added HRP-Ni remained in the supernatant of EAK-EAKH6 composite. 
89.5±13.3% and 83.1±15.0% of HRP-Ni were found unbound in the supernatant of pure 
EAK and pure EAKH6, respectively. Therefore, it can be deduced that approximately at 
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least 90% of the HRP-Ni bound to H6 domains in the assembly and was removed from 
solution by centrifugation. Although EAK formed the assembly and was centrifuged and 
filtered removed, HRP-Ni remained in the filtrate because it does not bind to EAK. It is 
possible that HRP-Ni could bind to EAKH6, but these complexes are likely low 
molecular weight species and therefore passed through the filtration step. Hence, the 
disappearance of HRP-Ni from the supernatant of EAK-EAKH6 is caused neither by 
non-specific adsorption to the assembly, nor by complexation with free EAKH6. Taken 
together, these results add to the evidence of integration of EAKH6 into EAK and that the 
composite display solvent accessible H6 domain.  These H6 domains extruding from the 
EAK-EAKH6 composite can be recognized by reactive agents, thus work as mounting 
sites to modify the peptide assembly. 
    Additionally, these results were repeated for samples taken from the supernatant with 
the EAK-EAKH6 formed and incubated at 37 °C, 5% CO2 for days, figure 4-6 c.  The H6 
domain was thus demonstrated to be stable in EAK-EAKH6 structure over one week. 
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(c) 
             
Figure 4-6: Probing H6 domains in EAK-EAKH6 composite. Peptide 
structures formed in PBS were incubated with HRP-Ni for 60 min at 4°C. 
Samples were then collected by centrifugation (16,000×g) and filtered (0.22μm) 
to remove residual aggregates. The amount of HRP-Ni remained in the filtrates 
(i.e. not bound to the structure) was quantified using a colorimetric method with 
TMB as the substrate (with reaction terminated with H2SO4, λ=450nm). (a) 
Concentrations of the enzyme were determined using a standard curve (range: 
0.125 ng/ml to 8 ng/ml) reflecting a linear function: y=1.04x-0.15(r2=0.98).  
Differences among EAK-EAKH6 and EAK, EAKH6 and PBS were statistically 
significant (*p<0.001, n=3) based on ANOVA and Tukey’s Multiple Comparison 
Test (α=0.05). (b) Color contrasts among and absence of aggregates in the 
samples. Samples with HRP-Ni added to buffered saline without EAK or EAKH6 
were included to reflect maximal enzyme recovery. (c) shows the stability of H6 
function in the composite kept in PBS at 37°C and 5% CO2 over seven days. 
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SUMMARY AND CONCLUSIONS 
    To transform the EAK β-sheet network into a structure for antibody immobilization a 
versatile mounting mechanism is needed. To this end, a modified EAK peptide with six 
histidines (H6) appended at the C-terminal was used to introduce mounting sites. H6 
domains can be recognized by anti-poly-histidine (anti-H6) antibodies and interact with 
metals such as nickel and cobalt through coordination bonds. The modified peptide, 
referred hereafter as “EAKH6”, was designed on the basis that the amphiphilic domain 
[AEAEAKAK]2 intercalates into the crossed β-sheets of EAK to form a composite in 
which the H6 domains freely accessible. The assumption is that the histidine appendage 
does not interfere with the ability of the amphiphilic domain to engage the same in EAK 
oligomers. The integration of EAKH6 in the EAK structures was examined using UV-Vis 
FTIR, CD and a biochemical assay (HRP-Ni). FTIR spectra clearly show the presence of 
imidazole ring in the EAK-EAKH6 composite. In the presence of EAK, EAKH6 
undergoes a distinct conformational change, from α-helix to β-strand. A biochemical 
assay based on the enzymatic reaction of HRP-Ni was performed to determine the 
accessibility of H6 domains in the EAK-EAKH6 composite. Results from this study 
show that the EAK-EAKH6 composite can capture up to 90% of the metal-enzyme 
conjugate, thus proving the functional property of H6 domains.  Collective interpretation 
of the results in the aforementioned studies confirms the integration of EAKH6 into EAK 
assembly and that the associated H6 domains are accessible.  
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CHAPTER 5 
FUNCTIONALIZATION OF EAK-EAKH6 COMPOSITE WITH PROTEIN A/G 
AS THE ADAPTOR  
 
INTRODUCTION  
    Results described in the previous chapter demonstrate that H6 domain can be 
introduced into the peptide assembly by the integration of EAKH6. H6 associated with 
the assembly can be recognized by anti-H6 antibodies and interact with the divalent metal 
nickel. In the current chapter, results will be shown to demonstrate the functionalization 
of the EAK-EAKH6 assembly via the H6 domain. Specifically, IgG molecules will be 
mounted onto the insoluble structure such that the (capture) antibodies are displayed and 
clustered. To this end, a linker is needed to connect the capture antibody and H6 domains 
of the assembly. Protein A/G, which contains six Fc-binding sites for immunoglobulins, 
will be used to form the construct on which IgG molecules can be concentrated for the 
purpose of binding cells or soluble molecules.  
    Protein A/G is a recombinant fusion protein with six Fc-binding domains combined: 
four from protein A and two from protein G.
[106]
 Protein A is a cell wall component 
produced by several strains of Staphylococcus aureus. It consists of a single polypeptide 
chain with M.W 42,000Da with four high-affinity (Ka=10
8
/mole) binding sites capable of 
interacting with the Fc region of IgG structures. Maximal interaction occurs at pH8.2, 
although good binding takes place at neutral or physiological conditions (pH 7.0-7.6) 
(figure 5-1 a).
[107, 108]
 Protein G is also a bacterial cell wall protein isolated from group G 
Streptococci. Native protein G contains two Fc-binding sites, as well as albumin and cell 
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surface interacting domains. In the recombinant form, the albumin and cell surface 
binding domains are eliminated to reduce nonspecific interactions. It has been reported 
that most mammalian immunoglobulins bind with greater affinity to protein G than 
protein A. Maximal binding occurs at pH 5, although good interaction is observed at pH 
7.0-7.2.
[109-111]
 Recombinant DNA of Fc-binding domains of protein A and protein G 
results in a chimeric protein with broader binding activity than either protein A or protein 
G alone. Recombinant protein A/G (hereafter referred to as rpAG) thus binds to all 
human and mouse IgG subclasses. Binding of rpAG is also less pH-dependent, with good 
interaction in the pH range between 5 and 8 (figure 5-1 a). 
[106]
 
    By taking advantage of the Fc-binding capability of rpAG, a bi-functional complex 
was designed by coating rpAG with both the capture antibody and an anti-H6 antibody. 
The EAK-EAKH6 assembly is thus functionalized via its H6 domains through anti-H6 
antibodies (figure 5-1 c). IgG is a “Y”-shaped macromolecule, with typical molecular 
weight greater than 150KDa. The structure consists of three distinct domains. Limited 
digestion with the protease papain cleaves antibody molecules into three fragments, 
yielding two identical fragments termed the Fab (i.e. fragment antigen binding) and the 
Fc fragment. The Fc domain plays an important role in the functions of antibodies by 
activating the complement pathway, or recruit cytolytic effects of phagocytes and natural 
killer cells via Fc receptors.
[4, 112]
 Such structural configuration and functional segregation 
allows one to use Fc as an anchoring site to display Fab for binding antigens, as 
demonstrated in the studies to be described in the following chapter.  
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Figure 5-1: Protein A/G and antibody. (a) Comparison of the binding 
characteristics of mouse IgG at various buffer pH levels.  Reprinted by 
permission from International Scientific Communications (ISC): [American 
Biotechnology Laboratory] (Vol.7 Page 42), 1989.  (b) Schematic of using protein 
A/G as the adaptor to mount the capture antibody to EAK-EAKH6. (c) Structure 
of an IgG and its fragments. Reprinted with permission from © 2005 Grand 
Sciences Publishing: [Immunobiology] (6th edition, Page17). 
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MATERIALS AND METHODS 
Protein A/G and antibodies 
    rpAG was obtained from Pierce (Rockford, IL, USA). This protein was expressed in 
Bacillus and secreted into the surrounding medium during fermentation. It was supplied 
as salt-free lyophilized powder. Upon receiving, it was reconstituted into a stock 
concentration of 2.5mg/ml in sterile deionized water, and stored as aliquots of 50μl in the 
freezer (-80°C) until use. The strong binding affinity of rpAG to mouse and rabbit IgG 
subclasses has been proved. Rabbit anti-H6 polyclonal antibody was obtained from 
AnaSpec, Inc (San Jose, CA, USA). This antibody was affinity purified and supplied as 
0.2mg/ml solution in PBS (pH 7.4) with 0.2% bovine serum albumin (BSA) and 0.05% 
sodium azide. It was stored in the refrigerator (4 °C) until use. Fluorescein isothiocyanate 
(FITC) conjugated anti-mouse CD8a antibody was obtained from BD Biosciences (San 
Jose, CA, USA). This fluorescent antibody was provided as 0.5mg/ml in aqueous 
buffered solution containing ≤0.09% sodium azide. Up on arrival it was stored in the 
refrigerator (4 °C) and protected from exposure to light。  
Loading antibodies onto EAK-EAKH6 assembly 
    The complexes of rpAG and antibodies were prepared by incubating the antibodies 
with rpAG. 0.1μg rpAG was coated with 1μg anti-H6 antibody first (molar ratio 1:3). The 
capture antibody, anti-CD8a antibody, 1μg (mole ratio of rpAG to anti-CD8a 1:3) was 
then added to make the complexes. Thus the six Fc binding sites of a rpAG were 
saturated, and each molecule of rpAG carried both anti-His6 and anti-CD8a antibodies. A 
FITC conjugated anti-CD8a antibody was used for the purpose of confocal analysis. The 
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complexes were then mixed with peptides solution, and the mixture solution was injected 
into 1ml PBS containing 10% fetal bovine serum (FBS) to initiate the insoluble structure 
forming. FBS was added here to minimize the nonspecific binding. Aggregates were 
mounted onto slides for confocal analysis. 
Preparation of primary murine splenocytes suspension 
    Six to eight weeks old female (certified virus free) C57BL/6 mice were purchased 
from Charles River Laboratories International Inc. (Wilmington, MA, USA) and housed 
in the Duquesne University Animal Care Facility. All experimentation was handled in 
accordance with institutional animal care policy. To obtain primary murine splenocytes, 
the spleen was removed from the mouse, and grinded in 5 ml Rosewell Park Memorial 
Institute (RPMI) medium (HyClone Laboratories, Inc. Logan, UT, USA) containing 10% 
heat-inactivated fetal bovine serum (FBS) (HyClone), 50 μM 2-mercaptoethanol (Acros 
Organics, Geel, Belgium), 1% antibiotics (penicillin/streptomycin) (Lonza Walkersville, 
Inc. Walkersville, MD, USA). The cells were then spun down and resuspended in ACK 
lysis buffer followed by incubation in ice for 5 min to remove red blood cells. After that, 
the splenocytes were purified by passing through a nylon mesh (70 micron pore size), 
washed and suspended in PBS containing 10% FBS to the final concentration of 1×10
6
 
cells /ml.  
Apply splenocytes to antibody mounted EAK-EAKH6 assembly 
    The anti-CD4 antibody mounted EAK-EAKH6 assemblies were formed as described 
above in 6-well plate containing 2 ml complete RPMI (10% FBS and 1% antibiotics 
included) in each well. Assembly formed with EAK alone with everything else was 
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included as a control.  2ml murine splenocytes suspension (1×10
6
 cells/ml) in complete 
RPMI medium was applied to each well to achieve a final concentration of 0.5×10
6
 
cells/ml. The plate was then incubated at 37°C for 24 hours.  The peptide assemblies 
were then imaged for investigation of their integrity. 
 Microscopic imaging  
    Peptide assemblies with cell captured were mounted onto microscope slides with 
ProLong Gold antifade reagent (Invitrogen, OR, USA). A Zeiss AxioObserver Z1 
inverted microscope (Carl Zeiss MicroImaging GmbH, Germany) was used to collect 
imaging data. The microscope is equipped with digital image correlation (DIC) capability 
illuminated by 100w bright-field and 300w liquid light-guide channeled Xenon light 
sources for white light and fluorescence wide-field observation. The bright-field images 
and fluorescent images are captured by QImaging MicroPublisher 22159 digital CCD 
color microscope camera and high-sensitivity Hamamatsu C9100-02 electron multiplier 
CCD camera, respectively. The images were analyzed using a SimplePCI imaging 
software program (Hamamatsu Corporation, Sewickley, PA, USA). 
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 RESULTS AND DISCUSSION 
    The objective of this study was to determine the ability of EAK-EAKH6 assembly to 
display a specific antibody via rpAG as the adapter, building upon the work described in 
chapter 4, which shows the presence and accessibility of H6 domains in the EAK-
EAKH6 assembly. In this study, a fluorescent conjugated antibody was used for detecting 
its association with the peptide assembly. 
Immobilization of FITC conjugated antibodies on EAK-EAKH6 assembly 
    Capture antibodies were immobilized on EAK-EAKH6 assembly by using rpAG as the 
adapter. rpAG (22 pmol) was coated with anti-H6 (67 pmol) and the capture antibody (67 
pmol), resulting in mole ratio of 1:3:3 (rpAG to antibodies) (table 5-1). Thus, all six Fc 
binding sites on rpAG should be saturated. The now bi-specific rpAG was then mixed 
with EAK and EAKH6 (dissolved in water), and injected into a volume of PBS 
containing 10% serum. The ability of the adaptor to concentrate antibodies on EAK-
EAKH6 was first tested using rpAG equilibrated with an anti-H6 antibody and a 
fluorescent (FITC)-conjugated anti-CD8a IgG.  
    rpAG complexed with the antibodies mixed with EAK-EAKH6 showed concentrated 
fluorescence (figure 5-2), while only a low level of fluorescence was observed when the 
antibody was complexed with the EAK assembly. These results indicate for the 
immobilization of the anti-CD8a antibody on the EAK-EAKH6 assembly. The assembly 
prepared with EAK only did not concentrate the antibody, suggesting a lack of interaction 
between the rpAG complex with the structure. When kept in serum containing PBS at 
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4°C for one week, the EAK-EAKH6/antibody construct remained intact, as evidenced by 
the fluorescence observed on day 7 of incubation (figure 5-2).   
    These data are consistent with the interpretation of the analytical results described in 
Chapter 4. In particular, the presence of functional H6 domains in the EAK-EAKH6 
assembly is reinforced. In addition, the current data confirm the feasibility of the design 
of using anti-H6 antibody coated rpAG to mount capture antibodies onto the assembly. 
Furthermore, in the presence of serum proteins, which saturated the non-specific binding 
sites, the complex did not bind to EAK assembly. One can therefore assume that the H6 
domains are indispensable for loading the FITC-conjugated antibodies.  
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 M.W Stock Conc.  Total mass used 
for the construct  
Moles used for the 
construct 
Mole Ratio 
rpAG 50kDa 0.25μg/μl 1.1μg 2.2×10
-11
 1 
Anti-H6 
antibody 
150kDa 0.2 μg/μl 10μg 6.7×10
-11
 3 
FITC-anti-
CD8a antibody 
150kDa 0.5 μg/μl 10μg 6.7×10
-11
 3 
EAKH6 2479.7 7.8 μg/μl 78μg 3145.5×10
-11
 1430 
EAK 1656.2 5μg/μl 200μg 12075.8×10
-11
 5489 
 
Table 5-1: Stoichiometry of rpAG, antibodies and peptides. Peptides 
assembly was formed by EAK and EAKH6 at mole ratio of (4:1). The six Fc 
binding sites of rpAG were saturated by anti-H6 and anti-CD8a antibodies, both 
at the mole ratio of 1:3 (rpAG to antibody). The mole ratio of EAKH6 to anti-His6 
antibody is about 500:1 to ensure there are plenty of H6 domains to bind with. 
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Figure 5-2: Displaying IgG molecules on (a) EAK and (b) EAK-EAKH6. (a1), 
(b1) incubated in serum containing PBS for 24 hours; (a2), (b2) incubated for 
5days; (a3), (b3) incubated for 7days. Peptide structures were mounted with 
rpAG equilibrated with rabbit anti-H6 Ab and a fluorescein-conjugated IgG with a 
molar ratio of 1:3:3 such that all six Fc binding sites on protein A/G are occupied 
by either antibody. Bovine sera (10% v/v) were included to minimize non-specific 
binding. The peptide structures were transferred to glass slides and analyzed 
using a Zeiss AxioObserver microscope (operating the SimplePCI imaging 
software). Images shown are representative of two independent experiments 
conducted. 
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    As stated above, each rpAG molecule has six Fc-binding sites for antibody. In order to 
use rpAG as the adaptor to bridge the capture antibody to the EAK-EAKH6 assembly, 
every rpAG molecule carrying the capture antibody must have at least one anti-H6 
antibody attached as well. To achieve this goal, rpAG was coated with anti-H6 antibodies 
at the mole ratio of 1:3 as the first step in the process of making the constructs. By this 
way, half of the antibody-binding sites in rpAG molecules were occupied and the other 
half remained available for the capture antibody. The assumption is that anti-H6 antibody 
molecules added are evenly equilibrated with rpAG. This strategy was validated by the 
results showed in figure 5-2. 
    The results in figure 5-2 support the use of rpAG-antibody complex to mount capture 
antibody onto EAK-EAKH6 assembly. However, it is possible that the capture antibodies 
lose their biological activities during the process. They could form aggregates, be 
denatured, or the antigen-binding sites be covered by other components of the assembly. 
Thus it is important to test the bio-function of the antibodies after they are mounted onto 
EAK-EAKH6 assembly. Further studies will be conducted to test the ability of peptide-
antibody construct to capture cells.  
 Cellular compatibility of EAK-EAKH6 assembly 
    Materials developed as injectables or implants must be compatible with cells. As a 
preliminary study, the integrity of the EAK-EAKH6 structure was examined when co-
cultured with leukocytes. Primary murine splenocytes suspended in complete RPMI 
medium were applied to mouse IgG mounted EAK-EAKH6 assembly. The samples were 
incubated at 37°C for 24 hours.  
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  The peptide assemblies were examined before and after incubated with cells, as shown 
in figure 5-3.  A group of peptide-IgG constructs formed in medium without any cells 
was included as a control. As the images showed, overall integrity of the peptide 
assembly remained largely the same after 24 hours culture with mouse spleen cells. The 
accumulation of cells metabolites did not impact the β-sheet structures. No apparent 
effects were seen from accumulation of carbonic and lactic acids released from metabolic 
active cells. Components in animal (bovine) serum, including peptidases and proteases 
appeared inert against the structure. Thus the results suggest that EAK-EAKH6 
composite can reasonably sustain typical environment of living systems. It should be 
noted that the issue of biological compatibility require long-term in vivo studies beyond 
the scope of this work.  
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Figure 5-3: Cell compatibility of EAK-EAKH6 IgG construct. (a) Images of 
peptide assemblies in the cell culture wells. Primary mouse splenocytes were 
applied with complete RPMI medium containing 10% FBS and 1% antibiotics. (b) 
Zoomed in (digitally magnified) images. 
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Concentration of IgG in vivo via EAK-EAKH6  
    The ability of the construct to assemble in vivo was examined in a preliminary study. A 
solution of EAK and EAKH6 dissolved in deionized water mixed with rpAG equilibrated 
with an anti-H6 antibody and IgG (conjugated with the PE dye) was injected 
subcutaneously next to B16 tumors established in living animals (figure 5-4 a). Mice 
received the injection were allowed to move freely in their cage and euthanized on the 
next day, with the tumors and the adjacent tissues excised for analysis. The subcutaneous 
small tumor was used as a reference point for ex vivo identification of the injection site.   
    All mice injected with the complex were found to behave normally, with no unusual 
eating, drinking or grooming activities observed.  Care was taken to preserve the tissue 
integrity when tumors were excised. The insoluble EAK-EAKH6 structure could be 
observed with Congo red staining (figure 5-4 b). Figure 5-4 c and d represent bright-field 
image and xenon wide-field image of a same region of the recovered peptide assembly, 
respectively. Observed was an area with significant red fluorescence, which could only 
come from the PE-conjugated IgG molecules, injected with the EAK-EAKH6 assembly. 
The locale of the fluorescence is in the same vicinity of the injection site.  In contrast, 
when IgG-PE was injected without the peptide assembly at a tumor established on the 
opposite flank in the same mouse, no fluorescence could be detected (Figure 5-5). These 
results indicate that free IgG administered in vivo failed to remain at the site of injection 
but congregated when injected with EAK-EAKH6 and rpAG (anti-H6). Based on these 
data, it can be concluded that EAK-EAKH6 serves to form His-tag displaying assemblies 
in vivo. Concentration of antibody sustains for at least 24 h in vivo in the subcutaneous 
space. 
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Figure 5-4: Self-assembly of EAK-EAKH6 in vivo. (a) A solution containing 
EAK, EAKH6, rpAG equilibrated with anti-H6 antibody and a IgG conjugated with 
the red fluorescent dye (PE) was injected subcutaneously adjacent to a B16 
tumor (~3 mm in diameter) established in a C57BL6 mouse. (b) After 24 h, the 
area (the tumor and surrounding tissues) was excised and imaged. (c) Bright-
field image showing the outline of the membrane; (d) Xenon wide-field image 
showing the red fluorescence concentration in the membrane. 
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Figure 5-5: Fluorescence conjugated anti-mouse IgG concentrated with 
peptide assembly in vivo. (a), (b) PE-IgG complexed with rpAG and anti-H6 
was injected with EAK-EAKH6 composite. (c), (d) same amount of PE-IgG was 
injected by itself. (a) and (c) are bright-field images of the injection sites next to 
the tumors. (b) and (d) are xenon sourced wide-field images of the fluoresce. . 
No fluorescence was detectable when IgG-PE was injected by itself at a tumor 
established on the opposite flank in the same mouse. 
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    Immunohistochemical analysis of self-assembling peptides injected in vivo did not 
show overt inflammation.
[68]
 Although these results suggest that self-assembling peptides 
are non-immunogenic, studies testing long-term immunogenicity in vivo have still to be 
performed. rpAG and the antibodies could dissociate and phagocytosed by APCs, but the 
high-affinity interactions render this unlikely. The generation of neutralizing antibodies 
against rpAG and/or the antibodies could occur in 10-14 days after digestion by APCs, 
but in the absence of adjuvant, these entities should elicit only weak and short-lived IgG 
or IgM responses. The use of humanized antibodies should reduce the overall 
immunogenicity of the constructs. Protein A has also been used in immunoadsorption 
treatments (apheresis) for rheumatoid arthritis and dilated cardiomyopathy 
(ClinicalTrials.gov Identifier NCT00558584).  The incidence of adverse events, mainly 
vasculitis, is low. 
[113]
 A Phase I clinical study of administering staphylococcal protein A 
(PRTX-100) directly into healthy volunteers has been completed (ClinicalTrials.gov 
Identifier NCT00517855).  The lack of safety concerns drove the initiation of an ongoing 
trial studying the effects of multiple doses of staphylococcal protein A in adult patients 
with idiopathic thrombocytopenia purpura (ITP) in Australia (ClinicalTrials.gov 
Identifier NCT00571467). These examples of clinical usage suggest an acceptable level 
of biocompatibility of rpAG. 
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SUMMARY AND CONCLUSIONS 
   The studies described in this chapter have implications for the applicability of the 
system. The data show that IgG molecules can be concentrated via rpAG-antibody 
complex directed toward H6 domains.  This observation opens the possibility of a system 
that can interact with cells and soluble molecules in a specific manner.  Building upon the 
data showing spontaneous integration and assembly of EAKH6 into EAK, the in vivo 
experiments demonstrates a similar process can take place in the subcutaneous space.  
The system proves to be amenable as an injectable material. A solution of EAK, EAKH6, 
rpAG, anti-H6 antibody and IgG-PE injected subcutaneously assembled to concentrate 
the fluorescent antibody at the injection site for at least 24 h.  Presumably, the triggering 
stimulus is the salt in the physiological environment. This stimuli-responsive nature of 
EAK-EAKH6 is particularly useful. Because the crossed β-sheets insoluble structure 
forms only in the presence of metal ions, the components of the construct can be kept as a 
soluble system, allowing injecting through regular syringes, without the need for surgical 
placement often required in the use of implanted drug delivery devices. Importantly, 
complexation of rpAG with the antibodies remained intact during the injection, sustaining 
the shear stress applied through the needle (25
5/8
G). Taken together, the data support the 
notion that EAK-EAKH6 can be used as a platform for displaying antibodies in vivo.  
Ultimately, I envision the design may change how therapeutic antibodies are used and 
delivered in man.  
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CHAPTER 6 
CAPTURE OF LEUKOCYTE SUBSETS IN FUNCTIONALIZED EAK-EAKH6 
COMPOSITE 
 
INTRODUCTION 
    Recent evidence has demonstrated that Treg cell-mediated immunosuppression is one 
of the crucial mechanisms of unsuccessful tumor immunotherapy. Approaches to 
physically deplete or functionally inactivate Treg cells have been developed to reverse 
the tumor induced Treg cell expansion.
[40, 42]
 Anti-Treg mAb can be used to deplete the 
cells through antibody-dependent cellular cytotoxicity (ADCC) or block signaling 
through surface receptors. The depleting anti-CD4 and CD25 have been tested in mice 
with some success, and the signal modulators anti-CTLA4
[7]
 and anti-GITR
[54]
 have 
shown promise. Several of these, including daclizumab (anti-CD25), and ipilimumab 
(anti-CTLA4) are being tested in humans. A common feature from the results of the 
clinical trials is autoimmune syndrome such as thyroditis (daclizumab) and colitis 
(CTLA-4).
[40, 42]
 Thus a more specific therapeutic strategy is required to prevent high-
dose and sustained therapy in refractory diseases. Another possible reason for the poor 
clinical efficacy is that although the level of Treg cells is increased in tumor 
microenviornment, the number of lymphocytes is still not comparable to tumor cells. The 
tumor infiltrated lymphocytes were found to be <0.5% of the entire tumor cellularity.
[41]
 
Given these, it is envisioned that a localized delivery system that enhance the functions of 
the aforementioned anti-Treg antibodies could be decisive as adjuvant in tumor 
immunotherapy. The EAK-EAKH6 structure characterized could be a potential carrier of 
the antibodies.  The objective of the research in this chapter was to determine the ability 
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of EAK-EAKH6 assembly to trap T cells specifically in vitro via mounted surface 
molecule specific antibodies. Achieving this milestone will provide an initial assessment 
of EAK-EAKH6-antibody construct as a viable platform for engaging specific subset of 
T cells in vivo. The rationale is that the selective and multiple binding between the 
surface molecules and the antibodies displayed by EAK-EAKH6 should render a 
particular type of T cells immobilized onto the peptide assembly. Anti-CD4 antibody was 
used in the experiments to trap Treg cells. The level of Foxp3 expression was monitored 
in the lymphocyte population since Foxp3 is the most distinctive marker for the 
regulatory lineage.
[114] 
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MATERIALS AND METHODS 
Apply murine splenocytes to constructed anti-CD4 antibody mounted EAK-EAKH6 
composite 
The purified unlabeled rat anti-mouse CD4 antibody, 0.5mg in 1.0ml of 100mM borate 
buffered saline (pH 8.2), was purchased from SouthernBiotech  (AL, USA).  rpAG was 
complexed with rabbit anti-H6 antibody and rat anti-mouse CD4 antibody at the mole 
ratio 1:3:3 as described in chapter 5. The rpAG-antibody complexes and EAK, EKAH6 
in water were then injected into 600μl serum containing PBS holded in BD FalconTM cell 
culture inserts (BD Biosciences, NJ, USA) with polyethylene terepthlate (PET) 
membrane (8.0 μm pore size) accompanied by BD FalconTM cell culture insert 
companion 24 well plate. The membrane insert made possible removal of residual 
peptides and antibodies through repeated washing steps. Murine lymphocytes were 
obtained from the spleen of a female C57BL/6 with late stage of melanoma, and made 
into lymphocytes suspension, as described in chapter5, in PBS containing 10% FBS to a 
concentration of 2×10
6 
cells per ml. 2×10
6 
cells were then applied to each well, and 
gently shake for 1 hour at 4°C. The unbound cells were rinsed away by serum containing 
PBS. This process was repeated for 4 times. The peptide assemblies with cell captured 
were stained with FITC conjugated rat anti-mouse CD25 antibody (SouthernBiotech, AL, 
USA), 2μg antibody per well, and mounted onto microscope slides for microscopy 
analysis. Unbound cells were collected for semi-quantitative reverse transcription 
polymerase chain reaction (RT-PCR). The procedure is illustrated in figure 6-1. 
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Figure 6-1: Schematic of applying murine splenocytes to anti-CD4 antibody 
mounted EAK-EAKH6 membrane. Lymphocytes were harvested from the 
spleen of mice carrying B16 tumors. Single cell suspensions (2x106 cells/ml), 
depleted of erythrocytes and monocytes, were placed onto aggregates of EAK 
and EAK-EAKH6 established on mesh filters (pore size: 8 µm) for 4 h at 4°C. 
This process was repeated four times. Samples on filters were transferred to 
glass slides and analyzed under microscope. Unbound cells were collected for 
PCR analysis. 
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Microscopic imaging analysis 
    Peptide assemblies with cell captured were mounted onto microscope slides with 
ProLong Gold antifade reagent (Invitrogen, OR, USA). A Zeiss AxioObserver Z1 
inverted microscope (Carl Zeiss MicroImaging GmbH, Germany) was used to collect 
imaging data. The microscope is equipped with digital image correlation (DIC) capability 
illuminated by 100w bright-field and 300w liquid light-guide channeled Xenon light 
sources for white light and fluorescence wide-field observation. The confocal capability 
is provided by three acousto-optic tunable filter (AOTF) software-selectable 
(488/568/647nm) Melles Griot Kr/Ar laser lines fed into a Yokagawa QLC 100 spinning 
disc confocal head that is capable of analyzing 360 frames/sec. The bright-field images 
and fluorescent images are captured by QImaging MicroPublisher 22159 digital CCD 
color microscope camera and high-sensitivity Hamamatsu C9100-02 electron multiplier 
CCD camera, respectively. The images were analyzed using a SimplePCI imaging 
software program (Hamamatsu Corporation, Sewickley, PA, USA). The cells were 
counted by the program of NIH ImageJ. 
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) 
    Total RNA of collected unbound cells was isolated using a SV total RNA isolation kit 
(Promega, WI, USA). The qualities and concentrations of template RNA were 
investigated by absorbance at 260nm and 280nm using a Beckman DU530 Life Science 
UV/Vis Spectrometer (Beckman Coulter, Inc., CA, USA). Coupled RT-PCR was 
performed using Masterscript Kit & Masterscript RT-PCR System (5 PRIME GmbH, 
Hambrug, Germany) in an Eppendorf MasterCycler (Eppendorf, Hamburg, Germany). 2 
μl of primer pairs (one reverse and one forward, 10μM each) specific for Foxp3 and β-
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actin (R&D Systems, Minneapolis, MN) were added to 0.1-0.5 μg of RNA sample in a 
reverse transcription (50 °C for 50 min) step, followed by denaturation (94 °C for 4 min). 
The amplification steps consisted of 35 cycles of template denaturation (94 °C for 45 s), 
primer annealing (55 °C for 45 s) and primer elongation (68 °C for 45 s). PCR products 
were separated in 2% agarose gel, visualized by of ethidium bromide staining, and 
analyzed using NIH ImageJ. 
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RESULTS AND DISCUSSION  
Evidence of CD25 positive T cells captured by anti-CD4 antibody mounted EAK-EAKH6 
composite 
    The EAK-EAKH6 structure was loaded with an anti-CD4 antibody to test the capacity 
of the design to capture CD4+ T cells. The construct was exposed to a mixed population 
of mouse lymphocytes (including CD4, CD8 T cells, B cells and NK cells). These cells 
were harvested from mice carrying B16 tumors, which have spleen populated with Treg 
cells. Cell suspensions were applied onto the EAK-EAKH6 anti-CD4 construct formed 
on polycarbonate mesh filters. Cells bound to the construct were stained with FITC 
conjugated rat anti-mouse CD25 antibody and examined under microscope.  
    Bright-field images were captured on the same region at different magnifications. As 
presented in figure 6-2, a greater extent of cell capture is evident in anti-CD4 antibody 
mounted EAK-EAKH6 assembly (a1 through a4) compared to that in the EAK aggregate 
(b1 through b4). Using ImageJ the cell density was estimated to be 200-1000 cells/mm
2
 
in the EAK-EAKH6 construct, whereas only 10-40 cells/mm
2
 were captured by the EAK 
structure. The micrographs show that cells are not adsorbed randomly at the surface, but 
are ordered in heterogeneous clusters. 
    The captured cells in the EAK-EAKH6 structure were examined for their identities.  
Figure 6-5 shows a representative for two independent experiments indicating that the 
cells captured in the EAK-EAKH6 construct express CD25. Most likely, the cells are 
Tregs. This result compliments the findings in the bright-field images to suggest that cells 
were captured specifically through the antibodies displayed with minimal non-specific 
cell adsorption to the EAK aggregate.  
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    Taken together, the data show that the design of EAK-EAKH6 and rpAG/anti-H6 can 
be used to display mAb for purpose of capturing specific cell populations. The structure 
formed by self-assembling structure with pores of about 5–200 nm have an extremely 
high water content, >99.9–99.5% or 1–5 mg/ml (w/v).[57] These structures closely mimic 
the porosity and structure of extra-cellular matrices, which allow tissue cells to reside and 
migrate in a 3D environment.  Hence these peptide scaffolds have been used for 3D cell 
culture, controlled cell differentiation, tissue engineering, and regenerative medicine 
applications. However, the non-specific adsorption of cells to the peptide assembly was 
suggested not to be stress resistible. As figure 6-2 a1-a4 showed, most of the EAK 
assembly adsorbed cells were washed away. In the meantime, the cells immobilized with 
anti-CD4 antibodies stayed within the EAK-EAKH6 assembly after washing steps, 
indicating a stable interaction with the peptide structure. This property is important for in 
vivo application, especially in the tumor microenviorment that has higher perfusion rate 
and interstitial pressure than normal tissues.  
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Figure 6-2: Capability of the anti-CD4 antibody mounted EAK-EAKH6 
assembly to capture cells. Lymphocytes were harvested from the spleen of 
mice carrying B16 tumors. Single cell suspensions (2×106 cells/ml), depleted of 
erythrocytes and monocytes, were placed onto aggregates of (a) EAK, (b) EAK-
EAKH6 established on mesh filters for 4 h at 4 °C. This process was repeated 
four times. Samples on filters were transferred to glass slides and analyzed at 5x 
(a1), (b1); 10x (a2), (b2); 20x (a3), (b3); 40x magnification (a4), (b4).  (c2), (c3), 
(c4) cells associated with EAK-EAKH6 were enumerated using ImageJ. (d) Cell 
count per area (mm2) at different magnifications was found related linearly (y=-
5.7x+321, R2=0.9789).  
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Figure 6-3: Laser confocal images of CD25 staining.  Cells bound to EAK-
EAKH6 (a) were stained with a fluorescein-conjugated Ab against CD25, a 
surface molecule expressed by regulatory T cells. The same experiment was 
performed with EAK aggregate (b) for comparison. (a1), (b1) bright-field images; 
(a2), (b2) Kr/Ar laser sourced confocal images. 
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Depletion of Foxp3 in unbound fraction  
    Unbound cells from figure 6-1 were collected and analyzed for Foxp3 expression level 
by semi-quantitative PCR with specific primers. Foxp3 is a distinct intracellular marker 
for Tregs.
[115]
 Cells without passing through the anti-CD4 construct were used as the 
control.  
    Figure 6-4 shows the Foxp3 expression in the respective cell fraction in agarose 
electrophoretic migration. As expected, only products of Foxp3 (177 bp) and β-actin (154 
bp) were detected. Band intensity was quantified to determine the relative amount of 
transcripts in the cells. Unbound cells collected from the EAK assembly showed a high 
level of Foxp3 expression, at approximately the same level with that of cells without 
passing through any peptide construct. In contrast, Foxp3 expression was found 
decreased by 90% in cells recovered from the EAK-EAKH6 construct. It can thus be 
concluded that regulatory T cells can be depleted from the heterogeneous lymphocyte 
suspension. These data are consistent with the microscopic images indicating that specific 
cell subsets are captured onto the anti-CD4 EAK-EAKH6 construct.  The ability of the 
functionalized EAK-EAKH6 assembly to specifically capture cells via mounted mAb 
was thereby confirmed in vitro. 
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Figure 6-4: Evidence of EAK-EAKH6 used to deplete a specific T cell 
population. The relative fractions of regulatory T cells remaining apart from 
EAK-EAKH6 were quantified using semi-quantitative PCR based on expression 
of Foxp3, a transcription factor that largely defines regulatory T cells. The cells 
with no peptide-antibody construct incubation (referred to as blank) were used as 
a control here to evaluate the effect of culture condition on the Foxp3 expression. 
The band sizes were consistent with predicted PCR products of Foxp3 (177 bp) 
and β-actin (154 bp). Data represent two independent experiments conducted. 
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        It has been established that Foxp3 is a crucial factor for the functional development 
of CD4+CD25+ regulatory T cells.
[114]
 Initial support for the role of Foxp3 came from the 
observation that high Foxp3 expression in peripheral and thymic CD25+ Treg cells in 
mice. Conversely, Foxp3 could not be detected in CD25+ conventional activated T 
cells.
[114]
 The expression of Foxp3 in CD4+CD25+ thymocytes in wild-type mice and the 
diminished numbers of CD4+CD25+ T cells in scurfy and Foxp3-knockout (Foxp3−) 
mice implied a role for Foxp3 in Treg cell development. Ectopic expression of Foxp3 in 
mouse CD4+CD25−Foxp3− T cells results in acquisition of suppressor properties. Foxp3 
appears to exert parallel functions in mouse and humans. In humans, Foxp3 is also highly 
expressed in CD4+CD25+ T cells with suppressor function and that Foxp3 gene transfer 
confers suppressor functions to naive human CD4+ T cells.
[33, 39, 114, 116] 
In light of these, 
the evidence presented above suggests the construct has the potential to regulate the 
abundance or accumulation of Treg cells in a defined microenvironment.      
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SUMMARY AND CONCLUSIONS 
    In the previous chapter (5), evidence was presented to demonstrate that rpAG, anti-H6, 
and EAK-EAKH6 could be combined to display mAb. The studies described in this 
chapter serve to extend the feasibility of the construct by mixing with mouse 
lymphocytes in vitro.  The EAK-EAKH6 construct captured significant number of cells 
(figure 6-2), and the lack of cells bound to the EAK construct suggest specific interaction 
in the former. Two lines of evidence support specificity. Cells bound to the EAK-EAKH6 
construct express CD25 (figure 6-3), and that unbound cells recovered had lower (90% 
decreased) level of Foxp3 transcript than that of the same from the EAK assembly (figure 
6-4). It can thus be concluded that the EAK structure first reported almost two decades 
ago could be transformed from a non-specific matrix to a cell-selective structure in the 
EAK-EAKH6 construct.  
    The EAK-EAKH6 composite coated with mAb can be loaded with bioactive 
molecules, such as siRNA. Unlike the traditional concept of targeted drug delivery, in 
which the therapeutic agent is required to travel through the systemic fluid to arrive at the 
target cells, the current concept relies on co-localization of target cells with the 
therapeutics. Characterization of this injectable system described herein is a step towards 
applying the concept “reversed drug targeting” by which target cells are brought to a 
reservoir of drug molecules. I have begun to explore this in two formats. First, the 
membrane could be loaded with nucleic acids (used as a model drug) in the membrane. 
Preliminary data (not shown) indicate a 90% loading efficiency of oligonucleotides in the 
EAK-EAKH6 membrane, but only approximately 30% of that loaded was released after 
seven days at 37˚C. A second option is to mount polymeric particles loaded with nucleic 
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acids in or on the membrane. In this case the nucleic acids are released as a function of 
particle degradation. Both scenarios are aimed to exploit the close proximity of target 
cells and bioactive nucleic acids co-localized on a defined structure.   
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CHAPTER 7 
CHARACTERIZATION OF POL-(D, L-LACTIC-CO-GLYCOLIC ACID) 
PARTICLES AS CARRIERS OF NUCLEIC ACIDS INTO PRIMARY 
DENDRITIC CELLS AND T CELLS 
 
INTRODUCTION 
    Dendritic cells (DCs) are pivotal in the regulation of immune responses.
[117]
 
Modulation of DCs phenotypes with oligodeoxynucleotide (ODN) as decoys or anti-
sense molecules can affect T-cell functions and immunity.
[118, 119]
 Direct administration of 
ODN in intact animals, however, results in unpredictable and often suboptimal effects.
[120]
 
This can be attributed to inefficient accumulation of the ODN inside DCs due to 
extracellular physicochemical (e.g., anionic charges of DNA) and enzymatic (e.g., 
nucleases) barriers.  
    Nanoparticles have been used as carriers of ODN to overcome these barriers.
[121, 122] 
The biodegradable co-polymer poly(D,L-lactide-co-glycolide) (PLGA) is a suitable 
building block for forming nucleic acids carriers.
[123, 124]
 PLGA particulates are stable in 
vivo
[125]
 and can be effectively engulfed into APCs by endocytosis.
[126, 127]
 Theoretically, 
a large number of DNA molecules can be internalized with each particle entry. A key 
remaining barrier, however, is that internalized DNA molecules are channeled to 
lysosomes and degraded. In vitro, this may be overcome by delivering a large amount of 
the DNA and hope that some would escape. This is an inefficient process and high local 
DNA concentration may not be possible to attain in vivo.  
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    Another challenge is the poor efficiency of loading macromolecules in PLGA particles 
because the DNA is often damaged during the encapsulation process. Several groups 
have addressed this by incorporating cationic species into PLGA to increase entrapment 
of the DNA. Capan et al. have detailed the physical characteristics of microparticles of 
plasmid DNA formulated with PLGA and poly-L-lysine (PLL).
[128, 129]
 Ravi et al. 
described the preparation and characteristics of cationic PLGA nanospheres with 
PVA−chitosan to adsorb DNA intended for gene delivery applications.[130] Li et al. have 
used calcium-phosphate to precipitate plasmid DNA to form PLGA microparticles.
[131]
 
Stearylamine
[132]
 and polyethylenimine (PEI)
[133]
 have also been used to encapsulate 
plasmid DNA into PLGA microparticles. Kasturi et al. have shown that plasmid DNA 
adsorbed on PEI-surface conjugated PLGA microparticles leads to enhanced gene 
delivery in macrophages.
[134]
 
   In the work presented in this chapter, O10H6, an ornithine–histidine cationic peptide, 
was employed to fulfill the dual functions of improving loading and enhancing the escape 
of DNA from lysosomes. It has been shown previously that O10H6 forms stable 
condensates with nucleic acids on the surface of carboxylate polystyrene microspheres 
and this self-assembled system can facilitate DNA uptake in DCs.
[135, 136]
 The imidazole 
in histidine facilitates endosomal escape by disrupting the osmotic balance of the 
vesicles.
[137, 138]
 Herein the physical characteristics and cellular uptake of PLGA 
nanoparticles loaded with ODN pre-condensed with O10H6 were examined. The results 
show that PLGAO10H6 is an effectual nucleic acids carrier capable of delivering ODN into 
primary DCs. Evidence is shown for the cellular internalization and escape of the ODN 
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from the lysosomal pathway in DCs. These results raise the prospect of applying DNA-
loaded PLGAO10H6 in DC modulation.  
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MATERIALS AND METHODS 
Peptide and oligodeoxynucleotide 
    The peptide O10H6 (figure 7-1 a; 1982 Da) was custom synthesized by Sigma-
Genosys (Houston, TX, USA) custom synthesis service. Crude peptides were purified by 
HPLC (>90%) and their identities were confirmed by liquid chromatography-mass 
spectrometry. Upon arrival, the lyophilized peptides were reconstituted in sterile ddH2O 
at a concentration of 200 μg/μl (100 mM) and stored in 50-μl aliquots at −80 °C until use. 
ODN with a phosphorothioate-modified backbone containing the NF-κB binding sites 
(sense strand: 5’-AGGGACTTTCCGCTGGGGACTTTCC-3’) were custom synthesized 
by Alpha DNA (Montreal, Quebec, Canada). The DNA was labeled with fluorescein 
isocyanate (FITC) at the 5’ end. PLGA (50:50; 16.5–22 kDa; I.V.= 0.66–0.80) was 
obtained from Polysciences (Warrington, PA, USA). Polyvinyl alcohol (PVA) (Fig3.1 a) 
with a molecular mass of 22 kDa and 88% hydrolyzed was purchased from Sigma-
Aldrich (St. Louis, MO, USA). 
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Figure 7-1: Materials and methods of particles preparation. (a) Chemical 
structures of PLGA, O10H6 and PVA used in making the particles. (b) A 
schematic diagram of the particle fabrication process. A double-emulsion solvent 
evaporation method was used.  
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Preparation of PLGAO10H6-ODN nanoparticles 
    PLGAO10H6-ODN particles were prepared using a double-emulsion (w/o/w) solvent 
evaporation technique (figure 7-1 b).
[139]
 5μg O10H6 was added to 200 μl of an aqueous 
solution containing 40 μg of the ODN and gently shaken for 0.5 h at room temperature. 
This aqueous solution was incorporated into a methylene chloride (MeCl2) solution of 
PLGA (3%, w/v) by sonication. A Fisher model 100 sonic microprobe was used to 
introduce 24 W of energy (over 2 min) to form this water-in-oil emulsion. This primary 
emulsion was added drop wise with energy input (24W, 4 min) into 20 ml of aqueous 
solution of PVA (0.5%, w/v) to form a water-in-oil-in-water emulsion. The resulting 
double emulsion was stirred for 4 h in chemical fume hood to allow the MeCl2 to 
evaporate. Particles were recovered by ultracentrifugation and washed twice with ddH2O 
to remove excess PVA and un-trapped DNA. The particles used in the experiments 
described were freshly prepared prior to each analysis. We have, however, determined 
that the particles can be freeze-dried, stored, and be reconstituted in distilled water. 
Freeze-dried PLGAO10H6-ODN retains 90% of their physical characteristics (particle size 
and zeta potential) upon reconstitution. Addition of sucrose (2%, w/v) improves the 
recovery to close to 100%. Loading efficiency was determined by dissolving the particles 
in chloroform (2 h constant shaking) followed by extraction with Tris-EDTA buffers. The 
aqueous phase was analyzed for DNA content with OligoGreen (Invitrogen/Molecular 
Probes, Eugene, OR, USA; detection limit 100 pg/ml) to determine the amount entrapped 
in the particles.
[140]
 Loading efficiency was calculated based on the amount of ODN 
determined divided by the amount of ODN initially added in the primary emulsion. 
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Particle size and zeta potential analysis 
    The Nicomp 380 ZLS analyzer (Particle Sizing Systems, Santa Barbara, CA, USA) 
was used to determine particle size distribution and zeta potential. Mean hydrodynamic 
diameter was measured with particles suspended in ddH2O. The radius was calculated 
using the Stokes–Einstein equation based on diffusion coefficient of the particles in the 
medium. Data were integrated over 10 min in duplicate experiments and were test fit for 
Gaussian and non-Gaussian functions. The instrument operates based on the dynamic 
light scattering principle, capable of detecting particle size ranging from 5 nm to 5 μm. 
Zeta potential measurement was performed with the samples diluted with ddH2O (pH 
approximately 7.2) The measurement is based on electrophoretic mobility of the sample 
particles when subjected to an electric field. 
Transmission electron microscopy and infrared measurement 
    Transmission electron micrographs were obtained using a JEM-100 CXII electron 
microscope (Jeol, Tokyo, Japan). A cool beam electron gun (60 kV) was used to 
illuminate the samples. A PLGAO10H6-ODN suspension was dried on a copper grid 
support (G200-CU; Electron Microscopy Sciences, Hartfield, PA, USA) and stained with 
1% uranyl acetate for image capture. Images were captured from films developed using 
high contrast D-19 developer (Kodak, Rochester, NY, USA). Reflectance FTIR spectra 
were recorded on a Thermo Nexus 470 Infrared Spectrometer operated at a spectral 
resolution of 0.5 cm
−1
 with 1024 scans. Particles were dried overnight in desiccators. 
Samples were analyzed under inert conditions are scanned over the range of 400–4000 
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cm
−1
. Independent measurements of PLGA, O10H6 and plastic support were obtained for 
subtraction.  
Mice and generation of primary DCs  
    Female certified virus free BALB/c (H-2
d
) mice (6–8 weeks old) were purchased from 
Hilltop Lab Animals (Scottsdale, PA, USA) and housed in the Duquesne University 
Animal Care Facility. All experimentations were handled in accordance with institutional 
animal care policy. Primary DCs were generated from mice using the Inaba protocol
[141]
 
with minor modifications.
[142, 143]
 Total bone marrow cells were harvested from femurs 
and cultured overnight in serum-free RPMI medium (Life Technologies, Gaithersburg, 
MD, USA). Non-adherent cells were then re-plated at 10
6
 cells/ml in 24-well tissue-
culture plates (Costar, Cambridge, MA, USA) in RPMI containing 10% heat-inactivated 
FBS, 50 μM 2-mercaptoethanol, antibiotics (penicillin/streptomycin/fungizone) (all from 
Life Technologies) and cytokines (5 ng/ml of murine GM-CSF and 5 ng/ml of murine 
interleukin-4; R and D Systems, Minneapolis, MN, USA) and maintained at 37°C in 5% 
CO2. On day 4, non-adherent cells were removed by aspirating 80–90% of the media and 
adherent cells were re-fed with culture medium (1 ml/10
6
 cells) containing GM-CSF and 
IL-4.  
    For flow cytometric analysis, cultured DCs on day 6 of differentiation were exposed to 
FITC-labeled free ODN (0.5 μM) or ODN encapsulated in PLGA or PLGAO10H6 
(estimated ODN concentration = 100 nM) in 2 ml of Opti-MEM media for 2 h at 37°C 
and 5% CO2. Particle density in the experiment was estimated to be 2.2×10
7 
particles/ml, 
based on the number of particles per unit area enumerated in TEM micrographs. After 
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incubation, cells were then washed with PBS and analyzed using a Beckman Coulter 
EPICS XL bench-top flow cytometer. At least 10
4
 events were sampled for each group. 
Confocal imaging 
    Cultured DCs were adhered to coverglasses, washed with PBS and incubated with 
PLGAO10H6-ODN for 2 h at 37°C. Dendritic cells have an intrinsic propensity to adhere to 
glass or plastic surface. A Fisher brand coverglass (22 × 22 mm) was placed in each well 
in the bone marrow cultures. On day 6, the coverglass was recovered and adhered cells 
were washed with PBS and fixed in 4% paraformaldehyde for 15 min at 4°C before 
mounting on slides with an anti-fade medium (MOWIOL 4-88, CalBiochem, Darmstadt, 
Germany). Images were collected using a Leica TCS SP-2 spectral microscope (Leica 
Microsystems, Wetzlar, Germany) with an argon/helium laser and FITC filter. 
Internalized DNA was visualized by fluorescence detection based on FITC-labeled ODN. 
Lysosomes were illuminated by staining the cells with LysoTracker Red DND-99 
(Invitrogen/Molecular Probes), a red-fluorescent dye that illuminates acidic 
compartments in live cells. 
Foxp3 specific siRNA and preparation of siRNA adsorbed PLGA naoparticles 
    Double-stranded murine Foxp3-targeted siRNA (21bp) was designed and synthesized 
by Ambion (Austin, TX, USA) (Figure 7-2). Upon arrival, the lyophilized siRNA were 
reconstituted in sterile ddH2O at a concentration of 0.5μg/μl (100 mM) and stored in 50-
μl aliquots at −80 °C until use. In the uptake study, the siRNA was labeled with 
carboxyfluorescein (FAM) at one of the 5’-ends. 
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Figure 7-2: Sequence of Foxp3-targeted siRNA. 
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    Plain PLGA particles were prepared in our lab using a double emulsion (w/o/w) 
solvent evaporation technique described above. Particles were recovered by 
ultracentrifugation and washed twice with ddH2O before lyophilization to remove excess 
PVA and PLGA fragments. 60 mg of lyophilized PLGA was first coated with 200 mg of 
O10H6 in 300 μL of ddH2O. To assure sufficient binding of O10H6 to the particles, the 
components were equilibrated in a 1.5 mL Eppendorf tube with gentle shaking for 2 
hours at room temperature on a mini shaker at a setting that is equivalent to the second 
lowest speed. The resulting positively charged particles (denoted as PLGAO10H6) were 
then equilibrated with the siRNA for an additional 30 min with gentle shaking at room 
temperature. The N: P ratio for O10H6 to siRNA was estimated to be 10:1. The final 
particle had siRNA condensed by O10H6 associated with the PLGA particle surface and 
was referred to as PLGAO10H6-siRNA. 
Physiochemical characterization of PLGAO10H6-siRNA 
    A Nicomp 380 ZLS analyzer (Particle Sizing Systems, Santa Barbara) was used to 
determine the size and zeta potential of plain PLGA particles and PLGAO10H6-siRNA 
particles.  
    In order to confirm the binding of siRNA onto the surface of PLGAO10H6, the 
electrophoretic mobility of naked siRNA or the respective siRNA complexes 
(PLGAO10H6-siRNA) was evaluated by agarose gel electrophoresis. Samples were 
analyzed in 1% agarose gel (MP Biomedicals, Solon, Ohio) with or without the addition 
of low molecular weight heparin sodium (Eikins-Sinn, Inc., Cherry Hill, NJ) (50 U/mL) 
that can release charge-bound nucleic acids. To test the protection effects of the particles, 
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free siRNA and PLGAO10H6-siRNA were incubated with 10% FBS at 37°C for overnight 
prior to loading in sample reservoir. 
Mice and cell line 
    Six to eight weeks old female certified virus free C57BL/6 mice were purchased from 
Charles River Laboratories International Inc. (Wilmingto, MA, USA) and housed in the 
Duquesne University Animal Care Facility. B16 (B6-derived melanoma)-F10 cell line 
was obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA) 
and cultured in ATCC-formulated Dulbecco‟s Modified Eagle‟s Medium (DMEM) 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics.  
Flow cytometric analysis of RNA uptake 
    Fresh splenic T cells from C57BL/6 were exposed to FAM-labeled free siRNA (3 μg) 
or PLGAO10H6-siRNA in 2 ml of Opti-MEM media for 4 h at 37ºC, 5% CO2. After 
incubation, cells were then washed with PBS and analyzed using a Beckman Coulter 
EPICS XL bench-top flow cytometer. At least 10,000 events were sampled for each 
group. 
In vivo effect of Foxp3 specific siRNA carried by PLGAO10H6 particles 
    B16-F10 cells (passage number 5-10) were seeded subcutaneously into six to eight 
weeks old female C57BL/6 mice. After 7 days, PLGAO10H6-siRNA particles were 
injected intra-tumorally. 48 hours later, mice were euthanized and the spleens were 
pulverized to make single cell suspension. For flow cytometric analysis, the splenic cells 
were stained for CD4, CD25 and Foxp3 with fluorescent-conjugated antibodies. For RT-
PCR analysis, these splenic cells were selected for CD4 positive population. Total RNA 
was extracted and one-step RT-PCR analysis was performed in an Eppendorf 
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MasterCycler (Eppendorf, Hamburg, Germany). Murine Foxp3 primer pairs (SuperArray 
Bioscience, Frederick, MD, USA) were used to generate cDNA from total RNA and 
amplify the product, and mice β-actin primer pairs were used for semi quantification 
purpose. The DNA products were analyzed by electrophoreses on 2% agarose gel and 
visualized by ethidium bromide staining.  
Tumor assay 
    Mice were inoculated with 0.5×10
6
 B16-F10 cells (passage number 5-10) in 0.2 ml 
PBS subcutaneously. The diameter of the tumors was measured with calipers twice at 
right angles to calculate the tumor volume. Each experiment group consisted of five 
mice. 
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RESULTS AND DISCUSSION 
    PLGAO10H6-ODN particles were fabricated from PLGA polymer with the ODN pre-
condensed with O10H6 using a double-emulsion/solvent-evaporation method (figure 7-
1b).
[139]
 In contrast to a similar lysine-based peptide, O10H6 is nontoxic to DCs.
[144]
 
Ornithine is a non-natural amino acid that contains a side chain (−CH2−CH2−CH2−NH2) 
that is fully protonated at physiological pH. The histidine imidazole (pKa~6.7) is partially 
ionized (<5%) at pH 7.4, but is progressively protonated as pH decreases. Once inside 
endosomes (pH 5–6), the histidines in O10H6 may act as a buffer and induce the vesicles 
to burst by promoting influx of protons and water
[137, 138]
 and release their content into the 
cytosol.  
Physicochemical characteristics of PLGAO10H6-ODN particles 
    The PLGAO10H6-ODN particles have an average diameter of 373.5±29nm (n=3) based 
on dynamic light scattering analysis (figure 7-3 a). Additions of ODN and/or O10H6 do 
not affect the particle size since blank PLGA and PLGA-ODN (referred to as no O10H6) 
have similar diameters, 379±34nm (n=3) and 391±43nm (n=3), respectively. Blank 
PLGA particles have an average surface charge of −14.4 ± 3.2mV (n=3), most likely due 
to the PVA (surfactant) adsorbed on the surface.
[145-147]
 As expected, addition of anionic 
ODN to PLGA (PLGA-ODN) results in a more negative potential (−17.3±1.8mV, n=3) 
compared to blank PLGA. Incorporation of the cationic O10H6 (in PLGAO10H6-ODN) 
leads an average potential of −16.9±5.2mV (n=3 figure 7-2 b). The changes in the zeta 
potentials are consistent with the respective compositions of the particles. 
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Figure 7-3: Physical characteristics of PLGAO10H6-ODN particles. (a) Particle 
size determined by dynamic light scattering. (b) Zetapotential: determined with 
samples suspended in ddH2O. (c) Transmission electron microscopy micrograph 
of PLGAO10H6-ODN (diluted 10 times) at 10
4 × magnification. Inset: An inverted 
image of a selected particle was analyzed for circularity using the NIH ImageJ 
software. Circularity was determined to be 0.7 based on the function 
4π×area/perimeter2 (a perfect circle would have a value of 1.0). All data are 
representative of at least three independent experiments. 
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    Transmission electron microscopy confirmed the spherical morphology (calculated 
circularity=0.7; 1.0 indicates a perfect circle) of the particles (figure 7-3 c). Loading 
efficiency of PLGAO10H6-ODN was determined to be 42.3%, which is in the same order 
of magnitude in microparticles formed with PLGA and poly-L-lysine reported by Capan 
et al.
[124]
 DNA loading in PLGA-ODN was poor, at only 1.3%. 
    A subtractive FTIR method
[148, 149]
 was used to confirm the presence of ODN in the 
particles (figure 7-4). The spectra of PLGAO10H6 and PLGAO10H6-ODN were collected 
with PLGA as the subtracted background. The addition of ODN clearly changes the 
spectral profiles. The alkyl groups of the ODN can be clearly identified by the peaks at 
2922 cm
−1
 and 2852 cm
−1
 assigned to C-H asymmetrical and symmetrical stretches 
(figure 7-4 a). In PLGAO10H6 (without ODN), the broader bands at 3051 cm
−1
 and 2944 
cm
−1
 can be attributed to the gauche conformation of the alkyl chains in peptides (figure 
7-4 b). DNA structure leads to all-trans conformation of alkyl bands and a more 
consistent structure across the sample compared to peptides. The sharpening of the peaks, 
taken together with the changes in zeta potentials, confirms the presence of the ODN in 
PLGAO10H6-ODN particles. 
  
115 
                                 
Figure 7-4: Transmittance infrared spectra of PLGAO10H6-ODN. (a) 
PLGAO10H6-ODN and (b) PLGAO10H6, both with PLGA as subtracted background. 
x-axis, wavenumbers (cm−1); y-axis, % transmittance. Data are representative of 
three independent experiments conducted. 
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Flow cytometric analysis of ODN uptake in primary DCs 
    Bone marrow-derived murine DCs were used as the target to determine the capacity of 
PLGAO10H6-ODN to deliver ODN into cells. We used flow cytometry to determine the 
frequency of cells that had taken up the ODN based on FITC fluorescence. Each analysis 
was conducted based on at least 10
4
 cells. Background fluorescence was determined in 
control cells that had not exposed to DNA or particles. Treatment with PLGA-ODN 
(broken line) results in lower uptake compared to PLGAO10H6-ODN (dark line) (figure 7-
5 a). Cells exposed to PLGAO10H6-ODN have a higher level of ODN than those treated 
with equivalent concentration of „naked‟ ODN (thin line). Collective analysis of three 
independent experiments confirmed that treatment with PLGAO10H6-ODN consistently 
resulted in superior uptake compared to PLGA-ODN or „naked‟ ODN (figure 7-5 b). We 
determined that 25–30% of the dendritic cells had taken up the ODN (labeled with FITC). 
With PLGA-ODN particles, the same analysis yielded uptake of less than 5%. This was 
expected because of the poor DNA loading in PLGA-ODN. Incorporating O10H6 into 
PLGA particles clearly contributes to the delivery.  
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Figure 7-5: Uptake efficiency of FITC-labeled ODN by various carriers was 
determined in murine bone marrow-derived DCs. (a) Histograms from a 
representative experiment of control DCs (shaded solid), ODN (thin line), PLGA-
ODN (broken line) and PLGAO10H6-ODN (thick line). (b) Composite analysis of 
data from three independent experiments showing percentage of cells taken up 
the ODN. Error bars represent standard error of mean. Control DCs were 
cultured under the same conditions with treatment (∗p <0.05). 
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Evidence of internalization and endosomal escape 
    Internalization of ODN into DCs was confirmed using laser confocal microscopy 
(figure 7-6). In concordance with the flow cytometric results, we observed consistent 
superior ODN accumulation in cells exposed to PLGAO10H6-ODN compared to PLGA-
ODN (figure 7-6). Again, this was expected because of the poor loading of DNA in 
PLGA-ODN. Diffused fluorescence can be seen in a cell exposed to PLGAO10H6-ODN 
(figure 7-6 b, see arrow), indicating non-sequestrated ODN in the cytoplasm.  
    To confirm the fate of the ODN in DCs delivered by PLGAO10H6-ODN, cells were 
stained with a LysoTracker (red) dye to illuminate acidic compartments. Based on the 
differential localization of green and red clusters, we concluded that DNA could escape 
from the lysosomes (figure 7-7). Delineation of FITC and red fluorescence in selected 
clusters confirmed that ODN (FITC) could be found outside of acidic compartments 
(figure 7-7 b, cluster 1). An example of internalized ODN sequestrated in an acidic 
compartment is also shown (figure 7-7 b, cluster 2). Cluster 3 represents an empty 
lysosome (figure 7-7 b). Inclusion of O10H6 in the current system is intended to facilitate 
loading and lysosomal escape of the DNA. Although it has been reported that PLGA 
itself can also facilitate endo-lysosomal escape by charge reversal in acidic 
compartments,
[150]
 the buffering capacity of the histidines in O10H6 may neutralize lactic 
and glycolic acids generated in the particle interior as the polymer chains are 
hydrolyzed.
[151-153]
 Thus, O10H6 may also serve to protect the DNA from degradation 
inside hydrated particles. It should be noted that Babensee and colleagues have reported 
that the effect of PLGA on dendritic cell maturation is dependent upon the density (or 
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surface area) of the particles.
[154, 155]
 In our experience, this can be controlled by using 
particles with high payloads (amount of DNA/density of particles), thereby minimizing 
the surface area of PLGA particles the dendritic cells encountered.  
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Figure 7-6:  Confocal image analyses of DCs incubated with (a) PLGA-ODN 
or (b) PLGAO10H6-ODN for 2 h at 37°C. The arrow indicates a region of diffused 
fluorescence. Mounted slides were imaged at 100× magnification on a Leica TCS 
SP-2 spectral microscope. Data are representative of three independent 
experiments conducted. 
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Figure 7-7: Intracellular fate of internalized ODN. (a) Image overlay of DCs 
stained with LysoTracker red and incubated with PLGAO10H6-ODN. (b) 
Delineation of the location of acidic compartments and ODN in the image based 
on the ratio of red and FITC intensity. Data are representative of two independent 
experiments conducted. 
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Delivery of anti-Foxp3 siRNA 
    Another application of the carrier system is to deliver RNA molecules aimed to 
downregulate specific functions in T cells. In many forms of cancer, Treg cells that 
express the protein Foxp3 are associated with cancer progression.
[40]
 These cells can be 
indentified by CD4 and CD25, molecules expressed on the cell surface. Foxp3 regulated 
in a dose-dependent manner the development and functions of Treg cells. Suppressive 
functions of peripheral Treg cells require a continuous expression of Foxp3.
[156, 157]
 
Studies have shown that downregulation of Foxp3 can increase the ability of other 
immune cells to destroy tumors, e.g. cytotoxic T cells (CTL) revert back to anti-tumor 
phenotypes.
[45]
 RNA interference (RNAi) is a mechanism in which RNA molecules bind 
to and degrade specific messenger RNA (mRNA) in a sequence-dependent manner such 
that expression of the encoded protein is terminated.
[158]
 Inhibition of Foxp3 expression 
can be accomplished by introducing double-stranded small-interfering RNA (siRNA) 
with sequence complementary to the Foxp3 mRNA. In vitro, the activity of siRNA is 
long lasting, with 50% knockdown observed up to 10 days, and is mainly limited by 
dilution of the siRNA through cell division. The activity of siRNA in vivo, however, is 
hindered by rapid degradation in biological fluids prior to reaching target molecules. 
Efficient application of RNAi requires a carrier system to facilitate the uptake of siRNA 
by cells.
[159] 
 
    In this chapter, nanosized PLGA particles coated with the polycation O10H6 (with the 
resultant particles designated as PLGAO10H6) was used to adsorb siRNA that bind to the 
mRNA encoding Foxp3. The surface molecules CD4 and CD25 were used in quantifying 
Tregs in flow cytometric analysis. The level of Foxp3 expression was estimated using 
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semi-quantitative PCR. The performance of the siRNA-loaded particles was determined 
in mice carrying B16 tumors in which Treg cells have been found to congregate.  
Physiochemical characterization of PLGAO10H6-siRNA Particles 
    Zeta potential measurement showed that plain PLGA particles have an average surface 
charge of -16.92±1.1mv. The surface adsorption of O10H6 and siRNA (figure 7-8 a) 
caused this negative charge neutralized, resulted in an average potential of -0.30±1.0mv. 
The size of the RNA-loaded particles remained below 300 nm in hydrodynamic diameter, 
figure 7-8.  
    Heparin is a highly sulfated glycosaminoglycan, which has a high negative charge 
density. In the electrophoresis, heparin was added to liberate RNA bound via ionic 
interaction. In figure 7-9 a, upper panel showed that RNA were retained in loading wells 
when complexed with PLGAO10H6. When heparin was added, comparable level of RNA 
was released from PLGAO10H6-siRNA particles (figure 7-9 a middle panel). Serum was 
used to test the ability of PLGAO10H6 to protect the RNA from enzymatic digestion and 
protein destabilization. Compared to free siRNA, which were mostly degraded, RNA 
complexed with PLGAO10H6 (PLGAO10H6-siRNA) remained largely intact after incubated 
with 10% FBS at 37°C for overnight, figure 7-9 a lower panel. The band intensity was 
quantitatively analyzed and summarized in figure 7-9 b. It shows that compared to free 
siRNA, which is totally degraded in serum digestion, approximately 60% of the siRNA 
were protected by PLGAO10H6 particulates and remained intact through serum incubation.  
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Figure 7-8:  Physical properties of plain PLGA and PLGAO10H6-siRNA 
particles. (a) Mode of RNA loading and physical properties. Particle size and 
zeta potential of (b) plain PLGA particles and (c) PLGAO10H6-siRNA particles. The 
adsorption of O10H6 and siRNA did not change the size range of PLGA particles, 
but neutralize the negative surface charge. 
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Figure 7-9: Gel electrophoresis of RNA complexes. (a) Agarose (1%) gel 
image. Heparin sulfate was added to liberate charge-bound RNA from the 
surface of particles. In the “+serum” groups, naked siRNA or the respective RNA 
complexes were incubated with 10% FBS at 37°C for overnight to test the 
protection effects of PLGAO10H6 particles. (b) Relative fractions of RNA were 
quantified with the free siRNA as the control. 
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Uptake of RNA into primary mouse T cells 
    Confocal and flow cytometric analyses have been performed to test if the particles 
could assist uptake of RNA into primary mouse T cells. The uptake efficiency of FAM-
labeled siRNA in mouse spleen T cells was improved from 3.2±0.2% for free siRNA to 
20.1±3.9% when carried by PLGAO10H6 particles. Furthermore, in CD4+ T cells, this 
level was increased from 2.7±0.2% to 27.1±1.3% when PLGAO10H6 was employed. These 
differences were statistically significant in three experiments conducted (p < 0.01), figure 
7-10 a and b. Approximately, one in four CD4+ T cells isolated from a mouse spleen 
took up FAM-labeled siRNA when loaded on PLGAO10H6, compared to one in 24 when 
free siRNA were applied. Confocal imaging revealed that the RNA was internalized into 
the T cells (figure 7-10 c). 
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Figure 7-10: Evidence of siRNA (fluorescein labeled) in mouse T cells.  (a) 
Histograms from a representative experiment of flow cytometric analyses. (b) 
Statistical analysis of data from three independent experiments. Error bars 
represent standard error of mean.  (c) Confocal images of mouse splenic T cells 
exposed to PLGAO10H6-siRNA. Primary mouse spleen T cells were incubated with 
PLGAO10H6-siRNA particles for 4 hours at 37°C. Images were captured by a Leica 
confocal microscope at 63× magnification.  
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In vivo function of PLGAO10H6-Foxp3siRNA particles in mouse B16 melanoma tumor 
model 
    B16 tumor-bearing C57BL/6 mice were treated with PLGAO10H6-Foxp3siRNA 
particles. Spleen T cells were taken from these mice and fluorescently stained for CD4, 
CD25 and Foxp3. Flow cytometric analysis showed that Treg cells, measured based on 
cells expressing a high level of CD25, decreased from 24% to 14% in splenic CD4+ T 
cells. While measured based on intracellular expression of Foxp3, Treg cells decreased 
from 14% to 11% in CD4+CD25+ cells, figure 7-11 c. RT-PCR analysis (figure 7-11 d) 
showed that Foxp3 transcripts were downregulated about 50% in CD4+ spleen T cells 
isolated from these mice. Negative RNA that does not target any endogenous transcript 
was used as a control for nonspecific effects on gene expression caused by introducing 
any siRNA. 
    In figure 7-12, retarded tumor growth was observed in mice subjected to PLGAO10H6 
complexed with Foxp3 siRNA. Although the tumor would grow out eventually, the 
growth was delayed at the primary phase. Particles were injected when lesions were 
visible (5-7 days after B16 inoculation). It is envisioned that the regimen would be 
effective as an adjuvant when combined with cancer vaccines or chemotherapy. Mice 
administered with the particles or particles complexed with the siRNA showed no overt 
signs of acute toxicities.  
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Figure 7-11: In vivo effects of PLGAO10H6-Foxp3 siRNA particles. (a) 
Schematic of in vivo function study. (b) Surface and intracellular molecules 
expressed by Treg cells. (c) Flow cytometric analysis showed that CD4+CD25high 
T cells and CD4+ CD25+Foxp3+ T cells were down regulated in vivo. (d) Foxp3 
mRNA expression in spleen CD4+ T cells taken from PLGAO10H6- siRNA treated 
mice. Bands identified were consistent with predicted PCR products of Foxp3 
and β-actin at 221 and 302 bp, respectively. Negative RNA, that does not target 
any endogenous transcript, was used as a control for nonspecific effects on gene 
expression caused by introducing any siRNA. 
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Figure 7-12: B16 melanoma tumor growth in mice treated with Foxp3siRNA-
loaded or empty particles. Each experimental group consisted of five mice. 
Error bars represent standard error of mean. The difference between the two 
groups is not statistically significant (p=0.137). In the group treated with 
PLGAO10H6-Foxp3siRNA, 5μg siRNA were used for each mouse.  
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SUMARRY AND CONCLUSIONS 
   The present study shows that efficient delivery of ODN into primary DCs can be 
achieved with PLGAO10H6-ODN. The change in the zeta potentials and the infrared 
reflectance analysis indicate the presence of both O10H6 and ODN in the particles 
(figure 7-3 and 7-4). The colloidal nature of the particles suggests the system is a stable 
formulation. The combination of PLGA and O10H6 in particle formation is superior to 
PLGA or with O10H6 alone in the delivery of ODN (figure 7-5 and 7-6). Importantly, 
internalized ODN can escape from lysosomal degradation, suggesting that effective 
concentration can be attained in the cytosol (figure 7-7). In conclusion, the physical 
characteristics and cellular uptake of DNA loaded particulates fabricated with PLGA and 
O10H6 were reported. This unique combination should be further investigated for 
developing carriers of DC modulators. 
     In the delivery of Foxp3 specific siRNA, the change in surface zeta potential and 
electrophoretic pattern of the complexes indicated adsorption of the RNA onto the 
PLGAO10H6 particles (figure 7-8).  The size of the RNA-loaded particles remained below 
300 nm in hydrodynamic diameter. Additionally, PLGAO10H6 particles protected siRNA 
from serum digestion (figure 7-9). Confocal and flow cytometric analyses showed the 
particles assisted uptake of RNA into primary mouse T cells (figure 7-10). Mice 
administered with Foxp3-siRNA complexed with the particles had lower frequency of 
Treg cells (figure 7-11 c) and decreased expression of Foxp3 transcripts (figure 7-11 d). 
Early results revealed that intra-tumoral injection of the Foxp3-siRNA particles caused a 
delay in B16 tumor growth in mice (figure 7-12). In conclusion, the polymeric particle 
PLGAO10H6 facilitated the delivery of siRNA in primary mouse T cells. When complexed 
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with PLGAO10H6, Foxp3 specific siRNA is effective in down-regulation the level of 
Foxp3 in vivo. 
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CHAPTER 8 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS FOR: A PEPTIDE-
BASED PLATFORM FOR DISPLAYING ANTIBODIES TO ENGAGE T CELLS 
     
    In this work, I investigated the EAK-EAKH6 composite as a mAb-displaying platform 
and a potential nucleic acids delivery system. In this concluding narrative, I summarize 
the main findings from the aforementioned studies and share some of my thoughts in the 
next step in advancing the concept towards application.   
    A series of experimental studies were performed to test the concept that assembly of 
amphiphilic peptides could be exploited biomedically through functionalization. Chapter 
4 contains data showing integration of EAKH6 into the EAK structures. When the 
mixture of EAK and EAKH6 was exposed to physiological concentration of salts 
solution, e.g. PBS, an insoluble, gel-like structure formed. Whereas EAKH6 itself 
remained in solution, about 50% of the EAKH6 was removed from the solution when 
mixed with EAK. The composite was found to be stable at 37°C for at least 7 days.     
Upon establishing the EAK-EAKH6 composite with H6 domains for binding, Chapter 5 
sets out to determine whether this design can be used to load mAb to the peptide 
assembly. rpAG proved to be a reliable adapter to link anti-H6 antibody and capture 
mAb. The data show unequivocally immobilization of mAb onto the EAK-EAKH6. 
Importantly, the construct could be formed in vivo; aggregates displaying a fluorescent-
labeled mAb could be observed when a mixture of EAK, EAKH6, rpAG, anti-H6 and 
IgG (PE) dissolved in water was injected subcutaneously next to a tumor in a mouse. The 
anti-CD4 construct was shown to capture CD4 positive cells in a mixture of mouse 
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lymphocytes. Collectively, the results indicate that the insoluble peptide structure can 
cluster mAb in which the antigen-binding function remains intact. This work thus raises 
the prospect of using EAK-EAKH6 as an antibody delivery platform to modulate 
immune cells inside or near pathogenic locales. The “reversed drug targeting” concept, to 
be elaborated below, requires a mechanism to build a reservoir of drug molecules for co-
localization with captured cells. To this end, polymeric particles were explored as drug 
loading mechanisms (Chapter 7).  
    Monoclonal antibodies have emerged over the past decade into a mainstay of 
therapeutic options for a wide range of diseases, including autoimmunity, inflammation, 
cancer and organ transplantation. However, the clinical efficacy of therapeutic antibodies 
is limited. It is caused by short serum half-life, systemic side effects, or lack of effector 
functions which are Fc-mediated antibody properties that involved in target cell 
destruction: antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent 
cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). As an 
alternative, additional functions can be endowed on antibodies by conjugation to other 
drugs. In cancer therapy, antibodies or the antigen binding fragments (Fab) can be 
conjugated with radioactive isotopes, chemotherapeutics, toxins or the surface of drug-
loaded particles/liposomes to create highly targeted agents.
[2]
 In diagnostic techniques, 
antibodies are conjugated to light-active molecules, e.g. quantum dots
[160]
, for live 
imaging. Additionally, drugs conjugated to insulin receptor antibodies can achieve 
significant brain delivery through receptor-mediated transport.
[161]
 However, using 
immobilized mAb to capture cells has not been examined extensively. This strategy could 
potentially provide a novel application of mAb, by which the limitations of rapid 
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degradation and poor tissue penetration can be avoided. Although this approach is 
restricted to cell surface molecule specific antibodies; and the target cells have to be 
leukocytes that are capable of migrating via diffusion, it suggests a new idea to design 
and use mAb.  
    Self-assembling peptides have been explored extensively for drug delivery, 
including small molecules and proteins. Most of them are loaded by physically mixing 
with the peptides; therefore the release kinetics are significantly varied due to various 
interactions (could be electrostatic interaction or hydrophobic interaction) between the 
drugs and the peptides. To achieve controlled delivery, self-assembling peptides can be 
biotinylated, which allows binding with high affinity to any molecule (such as a protein) 
that can be biotinylated using strepavidin.
[73]
 However, typical conjugation methods 
require the use of organic solvents, resulting in at least partial denaturation detrimental 
effects on the biological activity of themacromolecules. Self-assembling peptides can 
also deliver signals by fusion proteins designed with incorporating proteins at the N- or 
C-terminus of the sequence of self-assembling peptides by a linker sequence.
[74]
 This 
method is limited due to lack of versatility, since each peptide-drug conjugate would have 
to be custom synthesized. Our work demonstrated that H6 domain could be introduced 
into the EAK assembly as a way to introduce binding sites. Thus the points of 
functionalization are an integral part of the structure. This strategy confers a degree of 
flexibility, for the specificity of the construct can be readily changed by simply using a 
different mAb.  The most promising aspects are the injectability of all components as a 
solution and the reconstitution of the structure in vivo.  
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    Abnormally skewed lymphocytes populations have been reported in cancer patients. 
Although the primary solid tumor can be removed by surgery or killed by chemotherapy, 
the tumor-favored trend still exists in the patient‟s immune system, which allows the 
reoccurrence of the tumor, or even worse, metastasis. This work suggested an immune-
focused strategy as a potential post-surgery treatment to reduce the incidence of 
reoccurrence, rather than directly target the tumor cells. 
    The demonstrated ability to capture cells is an important validation. Conventionally 
“targeted drug delivery” refers to chemical (e.g. ligand) or physical (e.g. magnetic)-
guided localization of agents to diseased tissues (e.g. tumor). However, T cells are 
usually widely distributed in the pathogenic sites and difficult to be targeted. It has been 
reported that less than 5% of the entire tumor cellularity are infiltrated lymphocytes.
[41]
 
Therefore, the traditional drug delivery may not work efficiently. Taking the advantage 
that a specific subset T cells could be congregated in the peptide structure, we herein 
suggest a new concept of reversed drug targeting. In this reversed approach, the drugs are 
immobilized while the target cells are brought to the drugs. Even the antibody is not 
potent enough to cause the target cells destructed; other therapeutics can be pre-loaded to 
the peptide assembly. In the work of Chapter 7, we employed PLGA particles as delivery 
vectors for nucleic acids to DCs and T cells. These PLGA particles could be decorated 
with nickel by incorporating Ni-NTA-DOGS in the primary polymer solution. These 
PLGANi particles have been tested in a study described in chapter 9. It would be of great 
interest to load PLGANi particles as drug carriers onto the EAK-EAKH6 composite 
through coordination with the H6 domain. With each component characterized, it is thus 
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possible to develop a system to test the concept of reversed drug targeting by bringing 
specific cells (via mAb) to a reservoir of drug molecules (particles). 
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CHAPTER 9 
 The experiments described below were part of a separate project concerning genetic 
modification of allogeneic transplant tissues. The study lies outside the scope of the main 
thesis described in the chapters above but nevertheless represents an element in of my 
graduate work.   
MODULATION OF ALLOGRAFT IMMUNOGENICITY WITH IL-10 GENE 
PARTICLES 
 
INTRODUCTION  
    More than 20,000 patients undergo solid organ transplantation every year in the U.S 
(source: Organ Procurement and Transplantation Network: http://optn.transplant.hrsa. 
gov/). Organ transplantation improves the quality of life for patients suffering from 
otherwise incurable diseases, including those of cardiovascular nature and malignancies.  
Inhibitors of T cell receptor signaling (e.g. tacrolimus) represent the mainstay in 
managing transplant rejection.
[162-164]
 These agents exert their therapeutic effects by 
dampening the cytolytic actions of all T cells. Patients exposed to these drugs chronically 
have increased risks of developing opportunistic infections and malignancies.
[164]
 
Consequently, transplant recipients rarely live to normal life expectancy. In most cases, 
the initial encounter between the allograft and recipient‟s immune system dictates the 
outcome. Attenuating acute rejection improves the long-term viability and function of the 
transplant. The time between organ harvest and implantation provides an opportunity to 
modulate the immunogenicity of the allograft, prior to encountering recipient‟s T cells in 
vivo. We envision that during the transit period (up to 24 hours), between organ harvest 
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and implantation, gene treatment can be applied as an ex vivo intervention to generate 
selective immunosuppression. The health impact of the proposed research lies in 
developing new strategies enabling tapered use of non-specific immunosuppressive drugs 
in transplant recipients by reducing the incidence and severity of acute rejection.   
    Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has been used to induce 
allograft tolerance in animal models. IL-10 regulates the functions of neutraphils, mast 
cells, T cells, macrophages, and other tissues,
[165]
 but the protective effect of the cytokine 
on allografts is mediated primarily through DCs.
[166-168]
 DCs cultured with IL-10 have 
been shown to impair the ability of T cells to produce INF-γ,[169] a cytokine that drives 
the killing function of cytotoxic T cells (CTLs). In vivo, protection of allgrafts by IL-10 
producing DCs often develops concomitantly with the expansion of Treg cells.
[170-172]
 
Treg cells restrain the proliferation and activation of CTLs.
[173]
 Suppressive function of 
Treg cells are mediated by TGF-β[174] and CTLA-4.[175] In mice, Treg cells inhibit 
migration of CTLs from draining lymph nodes to allografts.
[176]
 Foxp3+ cells have been 
found in accepted allografts
[177]
 and in lymph nodes of animals with long-lived 
transplants.
[178]
 Because of Treg cells‟ potential to curtail allograft rejection, the success 
of the ex vivo IL-10 gene treatment will be measured based on Foxp3 expression in 
recipient T cells.
[118, 179-182]
 Because of DCs‟ ability to dictate the activities of naive T 
cells, protection of allografts can be achieved by inducing DCs to produce IL-10 to 
inhibit T cells activation in transplant recipients.
[117, 183]
 IL-10-producing DCs have been 
tested as cellular therapy in transplant models.
[183, 184]
 From a logistical standpoint, ex 
vivo treatment of allografts is superior to cellular therapy using the patient‟s own DCs.  
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    Genetic modification of DCs to express anti-inflammatory cytokines is proposed as a 
strategy to mitigate transplant rejection.
[185-187]
 A current challenge is to develop effective 
methods to transfer immunosuppressive cytokine genes into DCs without using viruses. 
Compared to chemical methods, viral vectors generally confer superior transfection 
efficiency, but humoral and cell-mediated immune responses triggered by viral 
components can interfere with the inhibitory actions of IL-10.
[188]
 Non-viral systems are 
less immunogenic; but it was thought that DCs do not divide in situ and thus refractory to 
non-viral methods of transfection without the aid of pro-inflammatory stimuli.
[189, 190]
 
Data emerging in the past three years, however, have challenged this assumption. Using 
live-cell imaging techniques, it has been demonstrated that up to 5% of mouse DCs 
undergo division in vivo.
[191, 192]
 Similarly, 2-3% of human DCs are proliferating in situ at 
any given time.
[191]
 The fact that DCs undergo proliferation when residing in tissue makes 
it possible for in situ gene transfer in DCs using non-viral means. 
   Studies performed previously in our lab show that PLGA modified with the cationic 
peptide O10H6 (PLGAO10H6) were effective in delivering a mouse IL-10 encoding 
plasmid (pIL-10) to skew bone marrow-derived DCs to downregulate T cell responses. T 
cells stimulated by the IL-10 gene-modified DCs exhibited characteristics of Treg cells, 
as evident by upregulation of Foxp3 transcription factor concomitant with an increase in 
TGF-β production. It can therefore be concluded that PLGAO10H6 complexed with pIL-10 
delivered an overriding suppressive signal to T cells. Physical characterization of 
PLGAO10H6-pIL-10 revealed a stable colloidal dispersion. DNA molecules carried by 
PLGAO10H6 were protected from serum digestion.
[193]
 To obtain a stronger binding 
mechanism with O10H6, nickel ions were incorporated into the matrix of PLGA particles 
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using the metal chelating lipid DOGS-NTA-Ni. These particles were referred to as 
PLGANi particles. Binding of O10H6 raised the surface potential of PLGANi from -17mv 
to +13mv. This change was partially reserved by the presence of free imidazole, 
suggesting the binding was mediated by nickel-histidine coordination. When compared to 
PLGA particles without nickel (40.8%), ODN bound to O10H6 coated PLGANi particles 
(PLGANi-O10H16) exhibited enhanced capacity (71.9%) to accumulate in DCs cultured in 
vitro. DCs exhibited cellular stress after exposure to PLGANi-O10H16-DNA, but this effect 
can be prevented by serum and was reversed overnight.
[194]
  
    In this chapter, PLGANi-O10H16 particles were used to carry pIL-10 to reduce the 
immunogenicity of skin allografts. The presence of DCs in skin explants was confirmed 
by MHC-II antibody staining. Successful transfection was evidenced by the increased IL-
10 release. Reduced immunogenicity was shown by lower INF-γ production in co-culture 
of skin grafts with allogeneic T cells.  
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MATERIALS AND METHODS 
Plasmid and PLGANi-O10H6-pIL-10 complexation 
    Plasmid encoding murine IL-10 (figure 9-1, pUMVC3-mIL10; 4563 bp) was obtained 
from Aldevron (Fargo, ND, USA), aliquot in distilled water and stored in -80°C until use. 
The IL-10 gene in this vector is driven by the cytomegalovirus promoter/enhancer with 
trimmed intron A and a rabbit β-globin polyadenylation signal.  
    PLGANi particles were prepared using a double emulsion (w/o/w) solvent evaporation 
method, which was described in chapter 7, with metal chelating lipid DOGS-NTA-Ni 
incorporated in the polymer MeCl2 solution. Briefly, 90mg PLGA and 0.6 mg DOGS-
NTA-Ni were dissolved in 3 ml MeCl2. To this organic phase 200μl ddH2O was added 
and sonicated (24W) for 2 min. The resultant primary emulsion was added drop wise 
with energy input again (24W, 4min) to 20 ml of ddH2O and the resulting mixture was 
allowed to evaporate for 4 h to remove MeCl2. Particles were washed twice in ddH2O and 
recovered by centrifugation. Plasmid loading was accomplished by first coating the 
particles (30μl from 4.5mg/ml stock) with O10H6 (60μg) followed by addition of 
plasmids (pIL-10, 5μg) in 300μl ddH2O.  
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Figure 9-1: Mammalian expression vector for mouse IL-10. (obtained from 
Aldevron, Fargo, ND.)  
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Generation of skin explants and IL-10 gene transfer 
    Donor skin was harvested from euthanized Balb/c mouse by cutting eat off at base. 
Ventral and dorsal sides of tissue at base of ear were gently pulled apart. The dorsal 
tissue was collected with internal surface down in serum free OptiMEM media 
(Invitrogen, OR, USA). To visualize the DCs in dorsal sheets, PE (phycoerythrin)-
conjugated I-A
d
 antibody was added to stain the MHC-II molecules expressed on the 
surface of DCs. PLGANi-O10H6-pIL-10 complex was added to the cultures and incubated 
for 2 hours at 37°C in 5% CO2. Media were then removed and replaced with fresh  
complete RPMI 1640 (Mediatech, VA, USA) containing 10% FBS and GM-CSF/ IL-4 
(R&D Systems, Minneapolis, MN). 
Co-culture of skin grafts with allogeneic T cells and ELISA 
    As the schematic shown in figure 9-2, transfected skin grafts were cultured with 
splenocytes of mismatched mice C57BL/6 (H-2
b
). The splenocytes were depleted of red 
blood cells and monocytes prior to co-culture. 1×10
6
 T cells were seeded with each skin 
graft in 1 ml complete AIM V medium (Invitrogen, OR, USA) and incubated for 24 
hours in a humidified 37°C, 5% CO2 incubator. Concentrations of IL-10 and INF-γ were 
determined in the culture supernatants using the ELISA DuoSet kit (R&D Systems, MN, 
USA) according to the manufacturer‟s protocol. 
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Figure 9-2: Schematic of co-culture of skin grafts and allogeneic T cells.  
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RESULTS AND DISCUSSION 
   Under confocal microscope, the presence of DCs in dorsal sheets isolated from mouse 
ear skins was demonstrated using red fluorescent-conjugated antibodies specific to the 
MHC-II molecule I-A
d
 expressed only on DCs and DC-like cells (figure 9-3 a). 
Successful transfection was evidenced in the increased IL-10 release by the explants. A 
2-fold increase (p=0.0002) in IL-10 expression was found in skin cultures transfected 
with PLGANi-O10H6-pIL-10 compared to control plasmid (figure 9-3 b). Reduced 
immunogenicity is shown by lower INF-γ production by allogeneic T cells mixed with 
skin exposed to PLGANi-O10H6-pIL-10. More than 5-fold higher INF-γ (p=0.001) was 
found in T cells stimulated by skin explants transfected with PLGANi-O10H6 complexed 
with control plasmid compared to those transfected with PLGANi-O10H6-pIL-10  (figure 9-
3 c).  In the same skin-T cell cultures, higher level (2-fold difference, p=0.005) of IL-10 
was produced when the IL-10 gene particles were applied compared to when a control 
plasmid was used (figure 9-3 d). These results show a definitive inhibitory state of donor 
DCs, and support that the IL-10 gene particles can reduce immunogenicity of the 
allograft in vivo. 
    The principle targets of the immune response to allogeneic grafts are the MHC 
molecules, which are highly polymorphic within species. Since laboratory mice are 
inbred, each strain is homozygous and has a unique halotype. For example, the MHC 
haplotype of Balb/c is H-2
d
, and C57BL/6 is H-2
b
.
[4]
 The recognition of allograft MHC 
antigen is the primary event that ultimately leads to graft rejection. T cells involved in 
graft rejection can be sensitized against alloantigens via one of two distinct pathways: 
direct and indirect. In the direct pathway, organ grafts carry with them APCs of donor
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Figure 9-3: Effects of PLGANi-O10H6-pIL-10 particles on the immunogenicity 
of intact skin explants. Excised mouse ears (BALB/c) were rinsed with 70% 
ethanol and split into dorsal and ventral halves.  Dorsal halves were cultured in 
OptiMem media and subsequently exposed to PLGANi-O10H6-pIL-10 particles or a 
control plasmid. After transfection skin, explants were incubated in culture 
medium for 48 h prior to mixing with T cells for an additional 24 h. The skin 
explants contain high density of DCs (384/mm2; enumerated using a Zeiss 
AxioObserver Z1 inverted microscope), as indicated by a phycoerythrin (red) 
anti-BALB/c MHC-II antibody with parenchmyal cells countered stained with 
fluorescein (a). Supernatants from skin (b) and skin-T cell cultures (d) were 
analyzed for IL-10 concentration and in the latter case INF-γ release as well (c). 
Student’s t-test was used to determine statistical significance of the ELISA 
results. Detection limits of IL-10 and INF-γ ELISA were 4 pg/ml and 15 pg/ml, 
respectively.  
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origin. These APCs leave the graft and migrate via the lymph to regional lymph nodes, 
activate those host T cells that bear the corresponding T-cell receptor. The activated 
alloreactive effector T cells are then carried back to the graft, which they attack directly. 
The ligand of the alloreactive T cell is the allogeneic MHC molecule itself. A second 
mechanism leading to graft rejection is the uptake of allogeneic proteins by the 
recipient‟s own APCs and their presentation to T cells by self-MHC molecules. This way 
is known as indirect allorecognition. Direct allorecognition is thought to be largely 
responsible for acute rejection, especially when MHC mismatches mean that the 
frequency of directly alloreactive recipient T cell is high.
[195, 196]
 Therefore, genetic 
modification of donor DCs to express immunomodulatory molecules represents an 
effective strategy to prolong graft survival.  
    When the naive T cells from C57BL/6 (H-2
b
) are exposed to mismatched Balb/c (H-2
d
) 
DCs in the skin grafts, they are activated to undergo proliferation, differentiation and 
production of effector molecules. Among them is a main cytokine INF-γ released by CD8 
effector T cells and TH1 cells. Hence the expression level of INF-γ is a good quantitative 
index of the extent of host T cells can be activated. The results showed in figure 9-3 
indicate a significantly decreased mixed reaction between host T cells and donor DCs by 
transfected with pIL-10.  A possible protection regimen for skin grafts by PLGANi-O10H6-
pIL-10 is suggested.  
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